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Resumen 
El cáncer es sin duda un alarmante problema sanitario a nivel global; las 
estimaciones prevén una tendencia alarmantemente creciente tanto para la tasa de 
incidencia como para las muertes relacionadas con el cáncer. Las actuales opciones 
terapéuticas combinan abordajes quirúrgicos y radiación con la administración 
sistémica de fármacos quimioterapéuticos. A pesar de los avances que se han hecho en 
las últimas décadas, los efectos secundarios vinculados a los fármacos anti-
cancerígenos tradicionales siguen siendo una preocupación principal junto con la 
pérdida de eficacia terapéutica y el desarrollo de mecanismos de resistencia. 
Los compuestos a base de platino, especialmente el cisplatino, son probablemente los 
fármacos quimioterápicos más comúnmente utilizados. Eficaz para el tratamiento de 
una amplia variedad de tipos de cáncer, los fármacos de platino se unen al ADN 
produciendo una distorsión de la doble hélice que provoca a la muerte celular 
programada. Junto con el cisplatino, hay otros dos fármacos de platino (II) con 
aprobación mundial, y tres más sólo aprobados en ciertos países. Más recientemente, 
los profármacos del platino (IV) también han ganado gran interés ya que permiten el 
suministro de un compuesto inerte que una vez dentro de las células cancerosas es 
capaz de producir especies citotóxicas de platino (II). Aunque ningún nuevo compuesto 
ha alcanzado la aprobación de la FDA en los últimos años, sigue habiendo extensa 
investigación en esta área que sostiene una gran promesa en la mejora de los 
tratamientos quimioterápicos. 
Además de la quimioterapia, el uso del propio sistema inmunológico del cuerpo para 
combatir el cáncer también ha surgido como una alternativa alentadora contra esta 
enfermedad. La denominada inmunoterapia ha atraído gran atención y una amplia 
variedad de herramientas, incluyendo anticuerpos, vacunas o agonistas de receptores 
TLR, ya han sido descritas para explotar este enfoque. 
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A pesar del gran número de avances que se han hecho en el desarrollo de agentes 
quimioterápicos e inmunoterapéuticos más seguros y eficaces, todavía hay que 
superar importantes desventajas. La mayoría de los enfoques inmunoterapéuticos 
implican costosos procedimientos que limitan su aplicabilidad. Los fármacos de 
quimioterapia más sofisticados, por otra parte, todavía carecen de la selectividad 
necesaria y producen graves efectos secundarios tales como toxicidad sistémica y 
quimiorresistencia. 
Los recientes adelantos en nanotecnología podrían ser la clave para lograr un 
tratamiento más seguro y eficaz contra el cáncer, superando los principales problemas 
relacionados con las terapias tradicionales. La posibilidad de utilizar nanopartículas 
para transportar los fármacos directamente a los tumores u otras áreas de interés 
permite una mayor selectividad con dosis más bajas y efectos secundarios reducidos. 
El uso de nanopartículas como vehículos de transporte de fármacos es, de hecho, el 
foco principal de este trabajo.  
Gracias a la vasculatura caótica y la falta de drenaje linfático efectivo de los tumores, 
se pueden diseñar nanopartículas de tamaños y formas específicas para lograr una 
acumulación selectiva en el tumor a través de transporte pasivo basado en el efecto de 
permeabilización y retención mejorada. Además, las extraordinarias propiedades 
fisicoquímicas de las nanopartículas permiten la integración de diferentes modalidades 
de imagen para el seguimiento tanto in vitro como in vivo de los sistemas 
administrados. 
Tanto las nanopartículas como los agentes terapéuticos empleados durante la tesis 
fueron seleccionados teniendo en cuenta la trayectoria y la experiencia previa del 
grupo. Como vehículos de transporte se han empleado nanopartículas de oro y de 
óxido de hierro, ambas caracterizadas por su biocompatibilidad y baja toxicidad. 
Además ambas preparaciones permiten la fácil incorporación de gran variedad 
ligandos en la superficie para así poder elegir la estrategia más adecuada para anclar el 
agente quimioterápico. Asimismo, aunque el principal objetivo de este trabajo ha sido 
el desarrollo de vehículos de transporte, tanto las nanopartículas de oro como las de 
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oxido de hierro ofrecen también la posibilidad se empeladas como agentes de 
contraste en diferentes modalidades de imagen molecular (resonancia magnética, 
rayos X, imagen óptica, etc.) y pueden también actuar como agente terapéuticos 
debido a su habilidad de generar suficiente calor como para dañar células de cáncer 
bajo un estímulo externo como luz o un campo magnético.  
Debido a la amplia experiencia del grupo en la síntesis de complejos de platino y su 
importancia como fármacos contra el cáncer, esta tesis describe la preparación y 
varios compuestos de platino con potencial citotóxico para su transporte a través 
nanopartículas. Sin embargo, el lugar de emplear fármacos de platino (II), la 
investigación se ha centrado en el uso de profármacos de platino (IV) que permiten el 
transporte de un modo inerte así como la posibilidad de usar los ligandos axiales para 
su funcionalización o anclaje. 
Por otro lado, se ha seleccionado el poly(I:C), un análogo sintético de ARN muy 
conocido por si capacidad inmunoestimuladora. La investigación para su uso en 
inmunoterapia y la creación vacunas contra en cáncer es  muy extensa pero a pesar de 
actual principalmente como activador del sistema inmune, también se ha demostrado 
que es capaz de inducir muerte celular a través de diferentes mecanismos. Esta doble 
funcionalidad resulta de gran interés ya que permitiría el use de un mismo compuesto 
para atacar el cáncer desde los dos enfoques, quimioterapia e inmunoterapia. 
Mediante el uso de nanopartículas como vehículo de transporte, se pretende en este 
caso promover su actividad como agente quimioterápico. 
Esta tesis está estructurada en cuatro secciones principales, una introducción 
general y tres capítulos experimentales, cada uno enfocado en el desarrollo de un 
vehículo basado en nanopartículas para el transporte de un agente anticancerígeno y 
la evaluación de su eficacia. 
El capítulo inicial tiene como objetivo ofrecer una visión general del cáncer como 
principal motivación de esta investigación; partiendo de conceptos generales, se 
Resumen   
 
4 
describen los enfoques terapéuticos hacia la enfermedad así como estrategias más 
avanzadas que implican el uso de profármacos basados en platino y agentes 
inmunoterapéuticos entre otros. Siendo el uso de nanopartículas la base de esta 
trabajo, este capítulo también introduce la nanotecnología y su aplicación para el 
tratamiento del cáncer, haciendo hincapié en el use de nanopartículas para el 
transporte de fármacos y profármacos. También se describen las funcionalidades 
adicionales que ofrece el uso de nanopartículas tanto en el ámbito de imagen como su 
uso intrínsecamente terapéutico y como la combinación de todas ellas permite el 
desarrollo de nanosistemas teranósticos que integran funcionalidades diagnósticas y 
terapéuticas en una sola plataforma. 
A pesar de que cada uno de los tres capítulos experimentales se centra en el 
desarrollo de un nanovehículo de transporte y su uso en conjunto con un fármaco o 
compuesto anticancerígeno particular, los tres capítulos siguen un esquema similar. El 
trabajo parte de la síntesis y caracterización de las nanopartículas que se van a usar en 
cada caso, para obtener un sistema soluble en agua y biocompatible que además 
permita la interacción con el compuesto de interés. La incorporación del compuesto 
activo se lleva a cabo a través de diferentes estrategias y una vez formado el sistema, 
se estudia la funcionalidad in vitro usando líneas celulares de cáncer. Además, en todos 
los casos se añade un componente fluorescente al sistema de transporte para 
comprobar que es internalizado por las diferentes células cancerígenas. 
Finalmente, a pesar de que no ha sido posible en todos los casos, una vez comprobada 
la funcionalidad in vitro del sistema, se traslada a estudios de eficacia terapéutica in 
vivo con un modelo tumoral de ratón. Para poder ver la biodistribución y la posible 
acumulación de las nanopartículas en el tumor, el marcaje radioactivo permite su 
seguimiento mediante técnicas de imagen nuclear altamente sensibles.   
■ El capítulo 2 describe la preparación de nanopartículas de oro revestidas con 
polietilenimina (PEI) y su aplicabilidad en el transporte de un agonista de TLR 
bien conocido, poly(I:C). Aunque el poly(I:C) es más comúnmente utilizado para 
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la inmunoestimulación, este trabajo tiene como objetivo promover sus 
propiedades quimioterapéuticas a través del transporte con la nanopartícula. 
■ Extendiendo la aplicabilidad de las nanopartículas de oro revestidos con PEI, el 
capítulo 3 se enfoca en el polímero cargado positivamente situado en la 
superficie de las nanopartículas, el PEI. Este trabajo se basa en la utilización de 
una estrategia novedosa basada en interacciones de esfera externa entre el 
polímero y un complejo de platino para administrar y activar un profármaco de 
platino (IV) en tres líneas celulares de cáncer diferentes. 
Este trabajo fue además publicado a lo largo de la tesis bajo el título “Enhanced 
cancer cell killing of a Pt(IV) prodrug promoted by outer-sphere coordination 
with polyethyleneimines” (A. Garaikoetxea Arguinzoniz, N. Gómez Blanco, P. 
Ansorena Legarra and J. C. Mareque-Rivas, Dalton Trans., 2015, 44, 7135.) 
■ Finalmente, el capítulo 4 ilustra el uso de una estrategia covalente para cargar 
un profármaco de platino (IV) en micelas de óxido de hierro. Los ligandos 
axiales del complejo permiten su incorporación a un fosfolípido PEGilado 
utilizado posteriormente para la formación de las micelas. Una estrategia de 
radiomarcaje libre de quelatos permitió el uso de técnicas de imagen nuclear 
para el seguimiento de la biodistribución in vivo del sistema en un modelo de 
tumor de ratón. Además, este capítulo también describe la eficacia terapéutica 
in vivo del sistema en el mismo modelo tumoral de ratón. 
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Summary 
Cancer is undoubtedly a major health problem worldwide; the estimates 
indicate an alarmingly increasing trend for both the incidence rate and cancer related 
deaths. Current therapeutic options combine surgical and radiation approaches with 
the systemic administration of chemotherapeutic drugs. Platinum based compounds, 
especially cisplatin, are the most commonly used chemotherapeutic drugs. Efficient for 
the treatment of a wide variety of cancer types, platinum based drugs bind to DNA 
producing a distortion of the double helix that leads to programmed cell death. More 
recently, platinum (IV) prodrugs have also gained great interest as they allow the 
delivery of an inert compound that once inside the cancer cells is able to render 
cytotoxic platinum (II) species. Besides chemotherapy, the use of the body’s own 
immune system to fight cancer has also emerged as an encouraging alternative against 
cancer. The so called immunotherapy is attracting major attention and a wide variety 
of tools including antibodies, vaccines or Toll-like receptor agonists have already been 
reported for exploiting this approach. Despite important advances that have been 
made over the last decades in the development of effective chemotherapeutic and 
immunotherapeutic agents, significant downsides and limitations still need to be 
overcome. 
 Recent advances in nanotechnology might hold the key to achieving a safer and 
more efficient cancer treatment. The possibility of using nanoparticles to direct the 
drugs to the tumours or other areas of interest allows improved selectivity with lower 
doses and reduced side effects. On the basis of the leaky vasculature and lack of 
effective lymphatic drainage of tumours, nanoparticles of specific sizes and shapes can 
be designed to achieve a selective tumour accumulation. This thesis has focused on 
the use of gold and iron oxide based nanoparticles as delivery vehicles for two 
different therapeutic cargos, a platinum (IV) prodrug and the synthetic dsRNA poly(I:C). 
Low molecular weight polyethyleneimine (LMW-PEI) coated gold nanoparticles, PEI-
AuNPs have been explored in chapters 2 and 3 for the delivery and enhancement of 
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the cytotoxicity of both a platinum (IV) prodrug and poly(I:C). The use of PEI not only 
allows the easy preparation of the aqueous nanoparticles, but also plays a major role 
in the interactions with both cargos; being a well-known transfection agent this 
positively charged polymer electrolyte can interact with the negatively charged dsRNA. 
Moreover, it can also be used to promote outer-sphere interactions with the platinum 
prodrugs. This versatile and simple system is able to effectively deliver both cytotoxic 
agents and achieve an enhanced cancer cell death in different relevant cell lines. 
Aiming for enhancing the therapeutic efficacy of the platinum (IV) prodrug, iron oxide-
filled micelles have also been explored as delivery vehicles. The PEGylated 
phospholipids forming part of the micelle structure can be modified to covalently 
attach the prodrug. Chapter 4 focuses on the use of this platinum-modified micelle 
construct as a proof-of-concept study against an aggressive murine melanoma model.  
In summary two different nanoparticle-based delivery vehicles have been 
prepared and characterized during this thesis. Their functionality and effectiveness has 
been explored for the delivery of two relevant cargos, a cisplatin platinum (IV) prodrug 
and a well known dsRNA. PEI-coated AuNPs have demonstrated to be very versatile, 
allowing the delivery of different agents, but at the same time specific as only the 
cytotoxic effect of poly(I:C) is promoted rather than its most commonly used 
immunostimulatory activity. Moreover, the platinum-modified IONP micelles have also 
been tested in vivo for the treatment of a very aggressive tumour model and proved to 
be efficient in delaying tumour growth and more importantly improving survival rates 
of treated animals. The importance of the results obtained is not in the improved 
anticancer effect, but also in the simple design and versatility of the constructs which 
opens up a myriad of possibilities towards cancer theranostics and combinational 
therapy approaches.  
  
1 
Cancer Nanotechnology: 
Nanoparticle-based drug 
delivery vehicles  
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1.1. Cancer: current perspective and treatments 
According to data from the World Health Organization (WHO) cancer is still one 
of the leading causes of death globally. Only in 2012 14 million new cancer cases were 
diagnosed and caused over 8 million deaths. Moreover, cancer incidence is expected 
to rise by up to 70% over the next two decades.1 This multifunctional disease 
originates when the natural cycle of cell growth and division breaks down and cells 
start to proliferate in an uncontrolled way (Figure 1). The abnormal cancer cells do not 
die when they should; instead they keep proliferating and generate abnormal cell 
masses called tumours.  
 
Figure 1. Schematics of the difference between the natural cell cycle and the 
malfunction of cancer cells leading to uncontrolled proliferation. 
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As these malignant tumours keep growing they spread and invade nearby tissues. 
Moreover, some cancer cells can break off and disseminate through blood or the 
lymphatic stream spreading to other parts of the body. This process by which cancer 
spreads from the primary tumour to another site in the body is called metastasis and 
once it occurs the cancer becomes harder to control.2,3 
Although there are over one hundred types of cancer, usually named according to the 
organ to cell type of origin, some particular types have a higher incidence or a higher 
rate of mortality. Prostate cancer for instance is the most common type of cancer in 
men among Europe, and the second worldwide with an estimated 1.1 million new 
cases in 2012 (Figure 2).1 
 
Figure 2. Estimated cancer incidence proportions in men in Europe for 2012.1 
Despite not being as common as prostate or breast cancers, melanoma skin 
cancer incidence has alarmingly increased in the last decades (Figure 3), with over 
230000 new cases diagnosed in 2012. Melanoma is the most aggressive form of skin 
cancer, and even though it mostly affects fair-skinned populations, it still represents 
the sixth most commonly diagnosed type of cancer.4 Additional problems associated 
with melanoma include  its evolution, the inefficacy of current treatments, and that it 
is highly prone to disseminations, with around 30% of cases developing metastasis.5 
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Figure 3. Melanoma skin cancer incidence rate in the US (1975-2013).6 
Either due to a worryingly high global incidence in the case of prostate cancer or the 
alarming increase and the highly metastatic nature of melanoma, research to develop 
new and more efficient cancer treatments has attracted major interest over the last 
decades. 
Current therapeutic options mainly involve local treatments, based on surgery 
and/or radiation. For the case of solid and localized tumours surgery is usually the first 
option, but it is useless for blood cancers and many cases where the cancer has already 
spread. The use of ionizing radiation to treat solid tumours is also a very common 
approach in clinics.7 Although radiation with a high energy photon beam is the most 
extended treatment modality, alternative treatment options such as proton8 or 
neutron9 beams are gaining interest due to their higher efficacy in treating tumours 
where other forms of radiation are inefficient. Nevertheless, while surgery and 
radiotherapy are the primary treatments of choice for local and non-metastatic 
cancers, the use of additional anticancer therapies such as chemotherapy and 
biological therapies is often needed.  
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1.1.1. Chemotherapy 
In spite of the interest gained by the alternative therapies, chemotherapy is 
undoubtedly the most common approach usually in combination with surgical and 
radiation therapies. Chemotherapy constitutes a systemic therapy for cancers, based 
in the intravenous administration of one or more anticancer drugs, which most 
commonly interfere with the cell cycle resulting in cell death. The potential of chemical 
drugs for cancer treatment dates back to World War I and II, where soldiers exposed to 
mustard gas were found to develop lymphoid aplasia.10 As a result of these findings, a 
nitrogen mustard derivative (Figure 4) was the first drug to be clinically tested and 
found to be effective against lymphoma.11 Closer in time, researchers also discovered 
the potential use of a folic acid derivative in leukaemia treatment.12,13 Remarkably, one 
of these folate analogues, methotrexate (Figure 4), is still commonly used to treat 
cancer.  
 
Figure 4. Chemical structures of the nitrogen mustard derivative tris(2-chloroethyl) 
amine and the folate derivative anticancer drug methotrexate. 
These two findings were fundamental for the development of modern 
chemotherapy, however, it took over a decade to find out the mechanisms of action 
they had in common, which involved their ability to interact with DNA and damage it 
resulting in cell death. The approach of DNA targeting for cancer treatment was the 
base for the development of a wide range of chemotherapeutic drugs, but it was 
Rosenberg’s accidental discovery of anticancer properties of cisplatin in the 1960s that 
resulted in a major landmark in the history of successful anticancer drugs.14 
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1.1.1.1. Platinum-based anticancer drugs 
Since its serendipitous discovery as an anticancer agent in the 1960s cisplatin 
(cis-diamminedichloroplatinum (II)) has been very successfully used for the treatment 
of testicular cancer and has shown good efficacy towards other types of cancer such as 
ovarian, bladder, head and neck and cervical cancer.15–17 Due to its major role in 
cancer chemotherapy, the mechanism of action behind the anticancer activity of this 
drug has been widely investigated. The generalized mechanism (illustrated in Figure 5) 
suggests that the neutral cisplatin molecule is first intracellularly activated by the 
aquation of one of the two chloride groups; this dissociation is indeed facilitated inside 
the cell due to the low chloride concentrations inside the cell.18 The activated platinum 
is then able to bind to nucleotide bases in DNA.19 Experimental results indicate that 
the binding occurs at the nucleophilic N7 position of the imidazole ring of purine bases 
(guanine (G) and to a less extent adenine (A)). Cross-linking occurs through the 
displacement of the remaining chloride ligand, typically binding to another G. Despite 
most interactions occurring within adjacent bases (intrastrand cross-links), adducts 
involving bases in opposite DNA strand can also be present (interstrand cross-links). 20 
 
Figure 5.  Schematic of the mechanism of action of cisplatin; initiated by uptake across 
the cell membrane, followed by the aquation process in the cytoplasm and binding to 
the guanine bases on the DNA strands to form intra and/or interstrand cross-links in 
the nucleus. 
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X-ray crystallography and nuclear magnetic resonance studies of cisplatin-DNA adducts 
also provided a better understanding of the mechanisms behind the anticancer 
activity. In essence, these studies showed that the formation of the cross-links causes 
significant distortion of the double helical structure of DNA. This distortion interferes 
with DNA replication and triggers cellular responses that generally result in apoptotic 
cell death.21 
The success and clinical impact of cisplatin however, comes with a cost as it is 
notoriously toxic to the kidneys and gastrointestinal tract and many patients develop 
cisplatin resistance. These issues led to the development of less toxic but active 
alternative platinum drugs. As a result, nowadays three platinum-based anticancer 
agents are approved worldwide for cancer treatment, cisplatin, carboplatin and 
oxaliplatin; in addition, other three platinum derivative anticancer drugs are approved 
in specific countries, nedaplatin (Japan), heptaplatin (Korea) and lobaplatin (China) 
(Figure 6). The success of carboplatin is based on the presence of a more stable leaving 
group, which significantly lowers the toxicity. Since its approval in 1989, carboplatin 
has become indeed the standard chemotherapy treatment for ovarian cancer in most 
countries.22 On the other hand, the importance of oxaliplatin relied on its ability to 
overcome cisplatin resistance and is now a front line chemotherapeutic for colon 
cancer.23 
 
Figure 6. Chemical structures of platinum based anticancer drugs approved for clinical 
use in cancer treatment. 
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In spite of the extensive use of these drugs, it has been over a decade since a 
platinum based drug has reached global approval for cancer treatment. Nevertheless, 
the search for more effective and safer platinum compounds has remained a very 
active field in the last decades. According to the SciFinder tool over 4700 compounds 
with the general formula cis-PtA2X2 have been reported, reflecting the diversity of 
complex perturbations introduced to the general framework that approved platinum 
drugs share.19 The wide variety of approaches include the incorporation of targeting 
units such as carbohydrates that target glucose receptors, steroid derivatives to target 
various steroid receptors over-expressed in cancer cells, or the use of folate and 
peptide based targeting. In addition, many other platinum derivatives such as 
polynuclear species and non-covalently binding platinum compounds have also been 
intensively studied.19 Besides cisplatin and all the aforementioned platinum (II) 
species, platinum (IV) complexes are also known to have anticancer potential since the 
initial discovery of cisplatin;24 however, it was only recently that considerable research 
efforts have been focussed on such compounds. 
1.1.1.2. Prodrugs: new approach in chemotherapeutics 
Unlike the aforementioned platinum (II) species, platinum (IV) complexes 
generally exhibit a low spin d6 octahedral geometry (Figure 7), rendering a higher 
inertness to the coordination sphere. Platinum (IV) complexes are more resistant to 
ligand substitution reactions than their square planar platinum (II) counterparts. 
Prepared through oxidative addition of the platinum (II) precursor, platinum (IV) 
complexes gain two axial ligands that can be further modified to confer improved 
properties such as lipophilicity, redox stability or improved cellular uptake to 
potentially overcome the unwanted side effects and resistance exhibited by traditional 
platinum (II) drugs. 
The prodrug concept is based on the general assumption that the more chemically 
inert platinum (IV) agents will only be activated inside the cells, where cellular reducing 
agents such as ascorbic acid or glutathione will produce a reductive elimination of the 
two axial ligands liberating the active platinum (II) species.25  
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Figure 7. General structure of platinum (IV) prodrugs. 
Different platinum (IV) anticancer prodrugs have undergone clinical trials (Figure 8), 
but the most promising one so far has been satraplatin, which reached advanced 
phase III clinical trials, but was finally not approved by the FDA due to the lack of 
overall survival improvement.26 Since the axial ligands are released upon intracellular 
reduction, the use of biologically active molecules in the axial positions has prompted 
the research for “dual action” platinum (IV) complexes.  
 
Figure 8. Chemical structures of platinum (IV) prodrugs that have undergone clinical 
trials. 
In the many attempts to prepare such dually active agents, different approaches have 
been reported. Ethacraplatin and mitaplatin are two of the most notable examples of 
cisplatin platinum (IV) derivatives engineered to implement a dual therapeutic effect 
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(Figure 9). Ethacraplatin has ethacrynic acid axial ligands over a cisplatin scaffold, 
which upon release inhibit glutathione-S-transferase in a bid to overcome cisplatin 
resistance.27,28 Mitaplatin on the other hand was reported to be able to selectively kill 
cancer cells over healthy fibroblasts thanks to the combined action of cisplatin and the 
two dichloroacetate molecules that also act on the mitochondria promoting 
apoptosis.29 Although these compounds showed promising in vitro results, more 
advanced studies and insights into the in vivo behaviour and efficacy are still needed as 
none of these complexes have been able to improve the therapeutic efficacy of 
cisplatin.25 
 
Figure 9. Chemical structures of the dually active cisplatin platinum (IV) derivatives 
ethacraplatin and mitaplatin. 
1.1.2. Cancer immunotherapy 
Over the past decades, the application of immunotherapy in cancer treatment 
has evolved from a promising new alternative to a consolidated option in clinics. Based 
on the ability of the body’s own immune system to act to destroy the cancer cells, 
immunotherapy has attracted great interest and many efforts have been dedicated to 
develop efficient tools to exploit this approach (Figure 10).  
Despite the immune system naturally being able to detect and destroy abnormal cells, 
cancerous cells often lay undetected due to a reduced expression of tumour antigens 
or the expression of proteins that induce immune cell inactivation. Immunotherapy 
focuses on stimulating the immune responses against cancer and counteracting the 
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signals that suppress the immune response. Many different approaches, including the 
use of antibodies (Abs), vaccines, immune checkpoint inhibitors, cell therapies or toll-
like receptor (TLR) agonists have been developed for this aim, and various systems 
already have been approved to treat a variety of cancers.30 
 
Figure 10.  Summary of different anticancer immunotherapeutic approaches. 
Particularly interesting for this thesis is the use of TLR agonists, which as it will be 
discussed later on, are not only valuable tools for immunotherapy, but can also act as 
chemotherapeutic drugs against cancer.31,32 TLRs are a type of pattern recognition 
receptors (PRR) expressed in cells of the innate immune system to detect pathogens 
such as bacteria or viruses. Upon activation these receptors are able to start a 
signalling cascade that can produce powerful pro-inflammatory responses as well as 
the activation of cells of the immune system such as macrophages or natural killer (NK) 
cells. Thanks to important advances in the understanding and development of 
advanced immunotherapeutic tools to fight cancer, this approach is gaining great 
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significance as a single therapeutic tool, as well as in combination with the previously 
described strategies like radiation or chemotherapy.33 
1.1.3. Limitations of traditional therapies 
Both local and systemic anticancer therapies have great advantages and are 
indeed the most common clinical approaches, but they all suffer from unwanted side 
effects on one or another way. While immunotherapy aims at a more targeted 
approach to limit side effects and has a bright future ahead, many of the options still 
require very costly and time consuming processes such as cell manipulation and many 
others still have not been able to show a revolutionary clinical success. The main 
drawback of conventional chemotherapeutic drugs on the other hand, is their lack of 
selectivity, often resulting in undesired side effects like systemic toxicity and resistance 
to the drugs.34 To describe de attempts to achieve targeted toxicity, the term “Magic 
Bullet” was coined on the late 19th century.35 In spite of remaining a purely theoretical 
concept for many decades, the rapid growth of nanotechnology for medical 
applications now promises the development of such sophisticated strategies aiming to 
overcome the intrinsic limitations of traditional drugs and lead to more effective and 
safer therapies for cancer treatment. 
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1.2. Nanotechnology based approaches in cancer 
Nanotechnology provides many benefits to various fields of modern medicine, 
but in particular is making a significant impact on cancer treatment and diagnosis. 
Starting from the basics, nanotechnology is the science regarding matter at the scale of 
1 billionth of a metre, hence a nanometre (Figure 11).  
 
Figure 11. Illustration of different objects with sizes down to the nanoscale. 
This rapidly growing research area deals with submicron moieties typically ranging 
from one up to several hundred nanometres in size, known as nanoparticles (NPs). 
Nanoparticles can be classified in two main categories depending on their 
composition; they can be organic or inorganic. Organic nanoparticles include 
liposomes, polymeric nanoparticles or carbon based materials such as carbon 
nanotubes or carbon dots. Inorganic nanoparticles on the other hand encompass 
metallic structures, based on gold or silver among others, semiconductor materials 
such as quantum dots or rare earth doped nanoparticles like up-converting 
nanoparticles (UCNPs).  
The main reason for the increasing interest in nanoscale materials and their 
applicability in biomedicine relates to the unique properties that the nanoscale 
produces, providing nanomaterials with an intermediate behaviour between bulk 
materials and discrete molecules. This singular behaviour however, is not a recent 
discovery. It has been applied from ancient times in sculptures and paintings. One of 
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the most characteristic examples of that is the Lycurgus cup (fourth century AD), which 
changed from an opaque green colour to a transparent red by just shining light from 
the inside (Figure 12); it was later revealed that the presence of silver and gold 
nanocrystals was responsible for this phenomenon.  
 
Figure 12. Images of the Lycurgus cup changing from green colour to a brilliant red 
when shining light from the inside. 
The development of modern technology allowed not only discovering this early use of 
nanomaterials and understanding of their properties and science, but also led to a 
wide range of new possibilities in the applications of nanoscale structures, not only in 
biomedicine but also in many other fields ranging from electronics to agriculture. The 
growing interest in applying nanotechnology to cancer is largely attributable to how 
the exceptional features of nanoparticles readily contribute in many different aspects 
such as drug delivery, biosensing, image-based diagnosis and even the intrinsic 
therapeutic nature of some nanomaterials.36 
1.2.1. The unique properties of nanoparticles 
Among the several properties that get affected when taking a material to the 
nanoscale, the Lycurgus cup serves as an example to clearly illustrate how the optical 
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behaviour of nanomaterials greatly differs from the bulk. Two very clear exponents of 
this unique feature are semiconductor nanocrystals and plasmonic nanoparticles. In 
both cases the physical confinement of the material to nanoscale dimensions produces 
very particular optical properties.37 In semiconductor nanocrystals, also known as 
quantum dots, the extremely small particle size causes the so called quantum 
confinement effect, where energy levels become discrete rather than continuous and 
as a result, the optical and electronic properties become strongly size dependent.38 A 
decrease in particle size produces a blue shift in the optical absorption of quantum 
dots (Figure 13), therefore by slightly changing the size or even the composition, the 
absorption and fluorescence emission of quantum dots can be effectively tuned. 
 
Figure 13. Size dependent fluorescent emission of semiconductor nanocrystals, 
quantum dots. 
For plasmonic nanostructures, the strong light absorption is produced by the surface 
plasmon resonance (SPR) phenomenon. This effect was first described by Wood and is 
related to the collective oscillation of the conduction electrons in the surface of a 
nanoparticle exposed to light.39,40 The point at which the amplitude of the oscillation 
reached maximum at a specific frequency is called SPR. According to Mie theory, this 
effect induces a strong absorption of the light that depends on particle composition, 
size, shape and structure among other things; when the shape of the particle is 
elongated for example, the SPR shifts towards higher wavelengths (Figure 14).41  
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Figure 14. (A) SPR effect in gold nanoparticles due to the collective oscillation of 
surface electrons with incident light of a certain wavelength. (B) Shift in the 
absorbance spectrum from gold nanospheres to gold nanorods of increasing length. 
Adapted from 41 
 Another very important characteristic affected by the size at the nanometre 
range is the magnetic behaviour of materials. The magnetic properties strongly depend 
on the size and morphology of the particles. In bulk state, magnetic materials are 
constituted of multidomains, but as particle size decreases to the micron or sub-
micron range, the particles become monodomains, leading to a ferromagnetic 
behaviour. If size is reduced even further, the resulting nanoparticles become 
superparamagnetic.42  
A very clear example of this behaviour can be observed in iron oxide nanoparticles 
where generally particles larger than 25 nm exhibit a ferromagnetic behaviour, hence 
  Chapter 1 
 
 
27 
no need of an external magnetic field due to long relaxation times. When the particle 
size goes below 25 nm, the material does no longer exhibit any hysteresis effect and 
becomes superparamagnetic, thus an external magnetic field needs to be applied.43 
 
Figure 15. Size dependent magnetic behaviour of iron oxide nanoparticles. 
Finally the small size of nanoparticles provides them with a large surface-to-volume 
ratio44 which means that surface atoms in these particles have higher energies, 
effectively making nanoparticles more chemically reactive than the bulk material. This 
property is not only key for the development of catalytic systems, but also extremely 
important for surface functionalization and drug loading purposes. 
All of these unique properties can provide strategic advantages over traditional 
molecular therapeutic approaches, with the successful application of nanomaterials to 
improve anticancer treatments becoming a revolutionary approach towards tackling 
the disease. 
1.2.2. Nanoparticle-based drug delivery vehicles 
Over the past decade, many efforts have been focused on the design and 
development of new drug delivery systems for improving cancer treatment.36,46,47 
Many of the most effective anticancer drugs being hydrophobic or poorly soluble, the 
use of nanoparticles as delivery vehicles can provide enhanced delivery, targeting and 
protection (Figure 16).  
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Figure 16. General features of nanoparticle based drug delivery vehicles. 
Nanomaterials are available in a wide variety of compositions, ranging from micelles to 
polymer based nanoparticles, fluorescent quantum dots or metallic nanoparticles, 
each having particular properties. The shape of these nanoparticles can also influence 
their biological function. Based on a variety of synthetic protocols the shape and size 
can be tuned to obtain a myriad of structures going from spherical nanoparticles, to 
more complex ones like nanocubes or nanostars. Finally the surface of the nanocarrier 
can also be readily modified to introduce either functional groups, hydrophobic or 
hydrophilic ligands or targeting moieties and cargos like antibodies, small molecules, 
drugs or proteins depending on the specific needs. 
The benefits of nanoparticle based delivery systems can be summarized in three key 
points. The first advantage is the possibility of overcoming the problems caused by the 
poor solubility and chemical stability of the traditional drugs,48 either attaching them 
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to the surface of a nanoparticle or through encapsulation within a water soluble 
nanocarrier. This will not only protect the drug but also confer an improved 
pharmacokinetic profile (e.g. solubility, stability, circulating half-life).  Second, the use 
of nanoparticles allows both passive and active targeting strategies to improve tumour 
accumulation. Such drug delivery systems can be rationally designed to accumulate in 
the tumour area taking advantage of the enhanced permeability and retention effect 
(EPR) or by attaching targeting moieties.49 Third, this approach also facilitates 
controlled release strategies by using stimuli-responsive nanocarriers.50,51 
Depending on the nature of the payload and the nanocarrier, three major 
strategies can be adopted to achieve drug loading: conjugation, encapsulation and 
adsorption. 
 
Figure 17. Schematics of the three main strategies for drug loading. 
Encapsulation is most commonly applied in the case of organic nanoparticles such as 
liposomes or polymeric nanoparticles, which can incorporate hydrophobic cargos and 
deliver them in a water soluble manner.52,53 The adsorption strategies are often based 
on either electrostatic or hydrophobic interactions, by which the drug can be retained 
and successfully delivered. An example is the electrostatic attachment of nucleic acids 
to positively charged nanoparticles in gene delivery systems.54,55 The conjugation 
approach involves the creation of a chemical bond between the drug and the 
nanoparticle, usually mediated by carefully chosen ligands or linker molecules. In all 
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cases the delivery vectors must not only transport the payload but also be able to 
release it in a specific location. 
 The ability to selectively accumulate the nanotherapeutic system in the tumour 
area is a key factor towards achieving a successful and efficient treatment. Both 
passive and active targeting approaches have been widely reported (Figure 18).56,57 
Passive drug delivery is based on exploiting the characteristics of tumour growth, and 
the well described enhanced permeability and retention (EPR) effect.58 First identified 
by Maeda and Matsumara in the 1980s, this phenomenon relies on the leaky 
vasculature and dysfunctional lymphatic drainage of tumours which allows small size 
nanoparticles to enter the interstitium and accumulate in the tumour.59,60 With the 
aim of accomplishing an increased delivery to the tumour a variety of active targeting 
strategies have been developed attaching diverse moieties to the surface of 
nanoparticles.61,62 
 
Figure 18. Schematic representation of (A) the EPR effect (passive targeting) and (B) 
active targeting strategies. 
The most commonly used targeting moieties include monoclonal antibodies or 
antibody fragments, small molecules, peptides, carbohydrates or aptamers recognized 
by specific receptors exclusively expressed on tumour cells or those with a clear 
overexpression compared to healthy tissue. Wang et al. reported the use of an anti-
epidermal growth factor receptor (EGFR) mAb (Cetuximab) as an active targeting 
ligand in IONPs for enhanced magnetic resonance imaging (MRI) sensitivity and 
thermal ablation of lung cancer in vivo.63 Shi et al. described a dual targeting approach 
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based on the use of a αvβ3 integrin targeting small molecule (tetrac) and hyaluronic 
acid (HA); another small molecule known to have specific affinity for CD44 cells.64 
Using this dual-targeting strategy in paclitaxel loaded solid-lipid nanoparticles (SLNs) 
the authors reported an improved antitumour therapeutic effect in a B16F10 
metastatic melanoma model. Lippard and co-workers used an aptamer targeting the 
prostate specific membrane antigen (PSMA) to improve the delivery of a platinum (IV) 
prodrug for prostate cancer treatment.65 Despite the great number of active targeting 
strategies reported over the last decade, these approaches have not achieved to date 
breakthrough improvements in terms of therapeutic outcomes. In fact a recent 
literature survey by Wilhelm et al. on this issue indicates that the median delivery 
efficiency has not improved in the past decade,66 suggesting that a more simple system 
based on passive accumulation of the nanoparticles in the tumour might also result in 
an effective cancer drug delivery system. 
Beyond the possibility of selective tumour accumulation and enhanced 
delivery, nanoparticle based systems also provide a higher degree of control over the 
drug release, another essential factor in anticancer therapy. For this reason the study 
of different strategies that impart the ability to trigger the liberation of the drug is a 
key aspect. Triggers can be classified into internal or external but in either case, the 
exposure to the proper stimulus must produce physical or chemical changes in the 
delivery system drastic enough to allow the release of the drug cargo.  
Internal stimuli involve changes in the microenvironment of the tumour compared to 
normal tissue such as pH, redox, or enzyme activity. A recent work by Cui et al. serves 
as example of internal stimuli responsive systems.67 The authors developed a two-step 
stimulus responsive gold nanoparticle-based delivery vehicle for the widely known 
anticancer drug doxorubicin (Figure 19). The incorporation of the drug to the 
nanocarrier is achieved via a conjugation mechanism, using lipoic acid as a linker 
between the carbonyl group of the doxorubicin and the gold nanoparticle. To confer 
further solubility and stability, the amino group of the drug is conjugated to a PEG 
moiety through a carbamate bond. When the system is internalized into the cells, the 
acidic pH in the lysosomes triggers the first release, cleaving the hydrazone bond with 
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the nanoparticle. When the PEG-conjugated drug is released into the cytoplasm, the 
second release reaction occurs catalyzed by stearase, yielding the free doxorubicin 
which can then enter the nucleus and produce the anticancer effect. The use of the 
gold nanoparticle as a delivery vehicle not only is reported to provide solubility and 
protection to the drug, but also to lead to an increased uptake and efficacy thanks to 
the dually triggered release of the doxorubicin. 
 
Figure 19. The structure of AuNP-NHN=Dox-mPEG and an illustration of its intracellular 
drug release mechanism.67  
External stimuli on the other hand include application of magnetic fields, light 
irradiation or ultrasounds. The use of light for example is an effective and non-invasive 
approach to provide controlled release of a chemotherapeutic drug. In many cases 
however, high energy UV light is needed, which apart from having a low penetration 
depth is also harmful to healthy tissue. Therefore the use of low energy near infra red 
(NIR) light is preferred as an external stimulus for clinical applications. An example of 
NIR light triggered drug release was reported by Fedoryshin et al. using up converting 
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nanoparticles (UCNPs) for the delivery and controlled release of the chemotherapeutic 
agent 5-fluorouracil (Figure 20).68 UCNPs are known for their ability to convert NIR 
light into high energy UV/visible radiation, which in this case is able to cleave the o-
nitrobenzyl linker between the drug and the carrier.  
 
Figure 20. Schematics of the NIR triggered drug release. NIR excitation of the UCNP 
resulting in upconverted emission at 364 nm, used for the photo-cleavage of the ONB-
FU bond and subsequent release of 5-fluorouracil from the UCNP surface.68 
1.2.3. Beyond drug delivery: nanoparticles as multimodal imaging and 
intrinsically therapeutic agents. 
The importance of nanoparticles goes way beyond their use as delivery vehicles 
for different anticancer drugs. Their unique properties also contribute to their use as 
imaging agents or contrast enhancers and even alternative therapeutic approaches 
using the intrinsic properties of the nanomaterials. Given that gold and iron oxide 
nanoparticles have been used during this thesis, the following sections will focus on 
these materials, their properties and recent advances as both imaging and intrinsically 
therapeutic agents for cancer. 
Gold is well known to be one of the most resistant and inert metals and is this 
bioinert nature that makes gold an ideal material for biological applications (Figure 21). 
Although being mainly a non reactive material, the strong affinity of gold for thiolated 
compounds or disulfide groups has been well described and investigated as 
functionalization strategy for gold nanomaterials.69 In addition, gold characterizes for 
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its ability to attenuate high energy radiation, making it a very interesting material for 
the development of X-ray contrast agents.70 Significantly, gold nanostructures are also 
able to produce heat under the proper light irradiation conditions, serving as 
potentially therapeutic entities for thermal ablation of tumour tissue and cancer 
cells.71 
 
Figure 21. Advantages of AuNPs. (A) Tuneable size a photography showing the change 
in colour of increasing size AuNPs, (B) Straight forward functionalization. (C) 
Biocompatibility. 
Iron oxide based nanoparticles (IONPs) on the other hand are abundant in 
nature and present in soils, natural waters, sediments and even in some living 
organisms such as magnetotactic bacteria.72 Due to their magnetic nature, they have 
been used in many applications ranging from magnetoreception and compasses to 
hard disks.73 IONPs are typically composed of maghemite (γ-Fe2O3) or magnetite 
(Fe3O4) and synthetic procedures nowadays allow the preparation of a wide range of 
shapes and sizes (Figure 22). In addition, the body’s natural ability to metabolize iron 
renders these materials great biocompatibility.74 IONPs have indeed been extensively 
studied as contrast agents for MRI, but their magnetic properties also contribute to the 
applicability as multifunctional platforms provided by magnetically guided drug 
delivery and heat based anticancer therapy. 
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Figure 22. TEM images of iron oxide nanospheres and nanocubes developed in this 
thesis, representative of the tuneable size and shape. Photograph illustrating the 
magnetic manipulation of IONPs. 
1.2.3.1. AuNPs and IONPs for biomedical and multimodal imaging 
Biomedical imaging is undoubtedly one of the mail pillars of cancer clinical 
protocols, providing structural and functional information with minimally invasive 
techniques. Although it plays a major part in many aspects such as detection, 
screening, staging, image guided therapy and assessment of the therapeutic response, 
the role of imaging techniques in early-diagnosis in particular has made an enormous 
impact in the reduction of cancer mortality.75 
A number of different imaging techniques are currently used in clinics, including MRI, 
optical imaging, ultrasound imaging, X-ray computerized tomography (CT) or nuclear 
techniques such as single photon emission computerized tomography (SPECT) and 
positron emission tomography (PET). All these modalities present their own strengths 
and weaknesses in terms of sensitivity, resolution and tissue depth penetration (Table 
1). Nuclear imaging techniques for example exhibit a very high sensitivity but limited 
resolution; MRI or CT on the contrary are able to provide very high spatial resolution 
and accurate anatomical information, but their sensitivity is rather low. Optical 
imaging based on fluorescence on the other hand is routinely used for studies at the 
cellular level, but the scattering and low tissue penetration complicate and limit in vivo 
applications. Given that none of the individual techniques is enough to provide high 
resolution anatomical information with a high sensitivity, many efforts have been 
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focused on the development of combined approaches involving multiple imaging 
modalities. 
Table 1. Comparison between different imaging modalities in terms of sensitivity, 
resolution and tissue penetration depth. 
Functional nanomaterials have become an ideal platform to combine the 
strengths of various techniques and develop multimodal imaging agents able to 
provide precise information at the anatomical, functional and molecular level (Figure 
23). The unique inherent properties of different nanomaterials and their readily 
modifiable surfaces allows the design of novel imaging probes with increased 
sensitivity, spatial and temporal resolution as well as a controlled biodistribution.76,77  
 
Figure 23. Representation of different imaging modalities that nanoparticles can 
provide towards multimodal imaging. 
Gold based nanomaterials offer excellent properties for various imaging modalities; 
fluorescent gold nanoclusters for instance can be prepared with excitation and 
Modality Sensitivity Spatial resolution Depth 
CT mM 50-200µm No limit 
MRI nM-µM 10-100µm No limit 
Optical nM >0.3µm <10cm 
li  i i i  i l l i   
  -  µ   li it 
I -  10-100 µ   li it 
tic l   0.3 µm  10 cm 
PET, SPECT pM 1-2 mm No limit 
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emission profiles tuned from the UV to the NIR regions, offering a great alternative to 
traditional dyes and fluorescent probes.78–80 Not only applicable in cellular studies, 
gold nanoclusters have also been reported for in vivo optical imaging applications.81 
The ability of gold to enhance X-ray contrast on the other hand, dates back to the 
1890s, when Wilhelm Roentgen took an X-ray image of his wife’s hand and the gold 
ring on her finger produced a greater attenuation than the bones. The attenuation is 
dependent on the electron density, thus atomic number of the elements present in the 
tissue; therefore gold is able to produce a stronger contrast than the natural elements 
present in the body. Compared to traditional iodine based contrast agents for CT, gold 
nanostructures show a 2.7-fold enhancement of the mass attenuation coefficient.82 
The enhancement, however, is proportional to the amount of gold localized in a 
certain area. Given the low sensitivity of the technique, high doses are required to 
obtain sufficient contrast enhancement. For this reason, development of gold based 
nanostructures that combine their intrinsic properties for optical or CT imaging with 
more sensitive techniques such as MRI or nuclear imaging have gained great interest. 
With the aim of developing dual CT/nuclear imaging nanostructures, many examples of 
radiolabelled AuNPs have been reported recently using radioisotopes such as 64Cu or 
89Zr for PET83–86 and 111In, 123I or 199Au for SPECT.87–89 Most of these systems rely on the 
attachment of external moieties like antibodies, peptides or chelators to achieve the 
radiolabelling. Zhao et al. reported a Cu64-alloyed gold nanoparticle system for 
combined PET/CT imaging,90,91 which avoids the traditional chelator-based strategy to 
introduce a radioisotope to a nanoparticle by the direct incorporation of the copper 
into the nanostructure’s lattice, forming 64CuAuNPs. This system could be clearly 
detected by PET/CT in both breast and prostate cancer tumour models.  
A more recent publication by Ge et al. described a novel combination of lanthanides 
and gold nanoparticles for CT/MRI dual imaging.92 The authors report a facile synthetic 
method to prepare gold nanoparticles by using oleylamine not only as reducing and 
stabilizing agent but also as a bridge between the gold and the lanthanide ions (Figure 
24). Both Gd3+ and Yb3+ are able to coordinate to the nitrogen atom on the oleylamine 
to form the conjugated system, which is further functionalized with PEG to achieve 
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water solubility and biocompatibility. Gd3+ is a well known contrast agent for MRI, 
having seven unpaired electrons is able to affect the longitudinal relaxation times of 
the water protons in the surrounding tissue to generate positive contrast, also known 
as T1 imaging. The high atomic number and electron density of both gold and 
ytterbium on the other hand renders a stronger attenuation of X-rays in CT imaging. 
The capacity of the system for dual-imaging was tested both in vitro and in vivo with 
tumour bearing mice confirming the applicability of this combined approach for cancer 
imaging. 
 
Figure 24. PEGylated lanthanide-AuNPs for CT/MRI dual imaging in tumour bearing 
mice (tumour region indicated with white arrows). Figure adapted from 92 
The potential of iron oxide nanoparticles to act as contrast agents for MRI was first 
described by Ohgushi and co-workers in 1978 for dextran-coated nanoparticles.93 
Under the magnetic field of a MRI scanner, the superparamagnetic nature of these 
nanoparticles induces a magnetic dipole moment that is able to perturb the magnetic 
relaxation of the surrounding water protons and cause a substantial shortening of their 
spin-spin relaxation time (T2).  This perturbation results in decreased signal intensity, 
hence a darkening of the area of the MR image. The efficiency of the contrast 
enhancement is indicated by the relaxivity coefficient (r2), a value obtained as the 
gradient of the plot of R2 (R2 = 1/T2) versus the molarity of the magnetic atoms. Both 
the size and the composition of the nanoparticles affect the r2 values as shown in 
Figure 25; within the size range where the superparamagnetic nature of the 
nanoparticles exists, the relaxivity coefficient increases with size.94 Regarding the 
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composition, the r2 values can also be increased by replacing some of the Fe
2+ ions by 
other transition metal ions such as Mn2+, Co2+ or Zn2+ to form doped-IONPs.95  
 
Figure 25. Changes in T2-weighed MR contrast of IONPs depending on the size (A) and 
the introduction of doping metal ions (B). 
Several iron oxide based nanoparticles have been approved by the FDA for MR 
contrast enhancement.96 However, the low commercial interest and the lack of 
improvement compared to gadolinium based T1 contrast agents caused the withdrawal 
of all of them from the market. Nevertheless many efforts are still focused on the 
development of more efficient iron oxide based contrast agents as extensive 
preclinical and clinical studies on the previously approved preparations already proved 
the excellent safety profile of these materials. New clinical trials are indeed planned 
for testing the iron oxide based drug Ferumoxytol, already approved for the treatment 
of iron deficiency, as an MR contrast agent.97However, as mentioned previously a 
single imaging modality is not able to provide sufficient information. 
Taking advantage of the aforementioned intrinsic capacity of IONPs to produce T2–
weighed MR contrast, many approaches have been described to introduce additional 
imaging modalities including optical, nuclear or CT based imaging.98,99 Regarding dual 
MRI/optical platforms the initial approach involved the use of traditional fluorescent 
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dyes like rhodamine or Cy5.5. The latter has been particularly interesting due to its NIR 
fluorescence nature and therefore deeper tissue penetration.100,101 More sophisticated 
alternatives have taken advantage of intrinsically fluorescent nanoparticles such as 
quantum dots,102 carbon dots103 or UCNPs.104 A great variety of hybrid systems has 
been reported, using electrostatic and covalent interactions, encapsulation strategies 
and also core@shell structures. As an illustrative example of the wide range of 
possibilities to develop hybrid systems, two distinct IONP-UCNP core@shell dual 
imaging probes have been selected.  
 
Figure 26. Schematic representation and TEM images of two relevant UCNP-IONP 
core@shell combinations for UCL/MRI imaging. (A) Nanoparticles consisting of UCNP 
cores with an iron oxide shell and (B) using IONP cores with a gadolinium based UC 
shell. Figure adapted from 105 and 106 
Li and co-workers reported the synthesis of NIR fluorescent UCNPs with an iron oxide 
shell to provide MR contrast (Figure 26A).105 The resulting system was successfully 
used for in vivo lymph node imaging in mice using both the up-converting 
luminescence (UCL) at 800 nm upon excitation with a 980 nm laser and T2 weighed MR 
imaging. Anker and co-workers on the other hand developed a PEGylated 
Fe3O4@NaGdF4:Yb/Er or Yb/Tm nanoconstruct able to combine UCL with both T1 and 
T2 MRI thanks to the presence of both IONPs and gadolinium ions (Figure 26B).
106 
Although the system was not tested in vivo, the authors assessed the UCL imaging up 
to 1 cm deep in tissue, as well as the non-toxic nature of the nanoparticles in breast 
cancer cells.  
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The design of radiolabelled IONPs for dual nuclear-MR imaging has also been 
extensively exploited. Radiolabelling strategies for both PET and SPECT radioisotopes 
have been described including 11C, 64Cu, 67Ga, 68Ga, 69Ge, 89Zr, *As, 99mTc, 111In and 
124I.107–118 In many cases, traditional chelating ligands such as DOTA or NOTA and 
radiolabelled moieties such as 89Zr-DFO or 124I-labelled serum albumin have been 
employed; more recently however direct chelator-free strategies have gained great 
interest. Pioneered by Chen et al. who reported a novel chelator-free radioarsenic 
labelling of IONPs for dual PET/MRI in vivo imaging,114 many groups have adopted 
similar strategies to produce dual imaging IONP nanoconstructs. Among them, Holland 
and co-workers described a novel and versatile heat induced approach to radiolabel 
IONPs, where they demonstrate the efficacy of the process for the chelate free 
labelling of FDA approved IONP-based MR contrast agent Feraheme with three 
different radioisotopes (89Zr, 64Cu and 111In).109 A more recent example by Mareque-
Rivas and co-workers takes advantage of the affinity of Ga3+ ions for magnetite to 
afford a direct chelator-free labelling of IONPs with 67Ga or 68Ga for dual SPECT/MRI or 
PET/MRI image tracked delivery of immunostimulatory molecules to the lymph 
nodes.110 
 Finally several hybrid systems that combine both gold and iron oxide 
nanoparticles for multimodal imaging have also been reported. Carril et al. synthesized 
gold-coated iron oxide gyconanoparticles for tri-modal imaging, combining MRI, CT 
and ultrasound imaging in a single platform.119 A similar core@shell strategy as 
followed by Shi and co-workers, but changing the morphology of the gold coating to 
form a gold nanostar shell around the IONPs.120 Further functionalization with 
polyethyleneimine and hyaluronic acid rendered biocompatibility to the system which 
was able to combine MRI and CT imaging both in vitro and in vivo using tumour 
bearing mice. Gu and co-workers on the other hand selected heterostructures Au-
Fe3O4 nanoparticles for a similar dual MRI/CT imaging approach in rabbits.
121 As a 
different alternative and taking advantage of the optical properties of AuNPs, Wang et 
al. made use of electrostatic interactions to adsorb fluorescent gold nanoclusters to 
the surface of negatively charged CTAB coated magnetic nanoparticles.122 These gold 
nanoclusters presented a bright red fluorescence under 365 nm UV light and the IONPs 
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retained their magnetic properties even after the formation of the hybrid system. The 
authors used this dual imaging system as a proof of concept and confirmed its 
biocompatibility and ability to act as a fluorescent probe in 293T cells. The potential 
use of these hybrid particles as T2 contrast agents was also assessed, showing a 
concentration dependent enhancement of R2 values. 
1.2.3.2. Intrinsic therapeutic properties of nanoparticles 
Although this aspect is not the focus of this thesis, cancer nanotechnology also 
exploits the inherent therapeutic properties of some nanoparticles. Both iron oxide 
and gold nanoparticles have the intrinsic ability to produce heat under certain 
conditions, which can be applied in a therapeutic approach, commonly known as 
hyperthermia. The exposure to elevated temperatures has been described to turn cells 
more sensitive to radiation and chemotherapy, serving as an adjuvant.123 If enough 
heat is produced however, cells can suffer irreversible damage due to the loss of 
membrane integrity, DNA damage, protein denaturalization or inhibition of 
biochemical pathways. While a moderate rise in temperature preferentially induces 
apoptotic mechanisms, temperatures rising above 46 ºC produce necrotic cell death.124 
Taking advantage of both passive and active targeting strategies, heat-producing 
nanoparticles can selectively accumulate in the tumour area, maximizing the local 
effectiveness of hyperthermia while limiting the exposure and damage to the 
surrounding healthy tissues. 
The characteristic SPR band of gold nanoparticles is not only responsible for a 
strong absorption, but also allows this absorbed light to then be converted into heat 
through a series of non-radiative processes, making gold nanomaterials ideal for light 
induced heat generation or photothermal therapy (PTT).125 A rational design of the 
gold nanostructures can provide a strong absorption in the NIR region – an ideal 
wavelength range considering the biological optical window that allows deep tissue 
penetration.126 Although simple gold nanospheres do not allow such long wavelength 
absorption, alternative structures such as silica-gold nanoshells, gold nanorods or gold 
nanocages have successfully been used in cancer PTT both in vitro and in vivo.  
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The first extensive in vitro study of gold nanoparticle mediated PTT was reported by 
Pitsillides et al. who used micro and nanosize gold nanoparticles to selectively  damage 
lymphocytes upon irradiation with a pulsed laser.127 The same year Hirsch et al. 
published the first in vivo application of NIR absorbing silica-gold nanoshells for the 
thermal ablation of a human breast carcinoma xenograft model in mice.128 Since then, 
many other examples of gold nanoshells for PTT have been reported, many including 
active targeting moieties to improve the selective accumulation in the tumour area.129–
133  
Despite the initial success of gold nanoshells however, AuNRs quickly gained wide 
interest as they can also be tuned to achieve strong NIR absorption and were found to 
be more efficient for light induced heat generation.134–136  Bhatia and co-workers for 
instance reported the photothermal treatment of breast cancer xenograft tumour 
models using PEG-coated AuNRs. Compared to nanoshells, these AuNR system shows a 
6-fold increase in heat generation and as shown in Figure 27, the mice treated with the 
PTT present a clear decrease in tumour volume as well as an extended survival rate.136 
Since then, more exotic gold structures have also been designed for PTT applications, 
including nanocages,137 nanomatryoshkas,138,139 nano-semicubes140 or hybrid 
nanoparticles92,120 among others. 
 
Figure 27. In vivo antitumour efficacy of PEG-coated AuNRs as PTT agents is a breast 
cancer xenograft model in terms of (A) tumour volume and (B) survival rate.141  
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Wang et al. for instance published a comparative study of gold nanohexapods, 
nanorods and nanocages for PTT.137 Using these three NIR absorbing gold 
nanostructures they first evaluate the light-to-heat conversion ability of all three 
materials and demonstrate how the addition of a PEGylated surface to improve the 
biocompatibility is especially important in the case of AuNRs (Figure 28). The authors 
also investigate the in vivo biodistribution in tumour bearing mice as well as the heat 
generation and PTT efficacy in terms of tumour metabolic activity and conclude that 
nanohexapods are the most promising structures for this biomedical application.  
 
Figure 28.  Comparative study of gold nanohexapods, nanorods and nanocages for PTT. 
(A) Plot of the average temperature increase of the tumour area upon irradiation (808 
nm) with the PEGylated gold nanostructures and (B) thermographs of the tumour 
bearing mice receiving the treatment at different irradiation times. Adapted from 137 
Besides AuNPs, thanks to their magnetic nature IONPs also have the intrinsic 
ability to produce enough heat to be applicable in hyperthermia treatment. Rather 
than through a light induced mechanism, IONPs generate heat when subjected to an 
alternating magnetic field (AMF) through the Néel and Brownian relaxation processes 
shown in Figure 29.72 While the Néel relaxation is caused by the continuous 
reorientation of the spins of the nanoparticles under the AMF, the Brownian relaxation 
component relates to the friction caused by the physical rotation of the nanoparticles 
in the surrounding media.  
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Figure 29. Heating dissipation processes of IONPs under an AMF. Néel relaxation is 
related to the alignment and relaxation of the spins while the Brownian relaxation is 
determined by the rotational mobility of the nanoparticles. 
Known as magnetic hyperthermia, the use of magnetic IONPs for thermal 
treatment was first explored by Gilchrist et al. in 1957 as a tool to destroy lymph node 
metastases in dogs.142 However, still today some degree of controversy exists over the 
results due to the lack of control experiments. In spite of the debate, many groups 
continued this research line since its initial discovery due to the very appealing 
advantages of the technique. The use of an AFM presents no restrictions in tissue 
penetration and the selective tumour accumulation as well as the possibility of 
magnetic guidance of the nanoparticles allows a selective treatment with minimal 
damage to the surrounding tissue. In fact the first clinically applicable magnetic 
hyperthermia system was developed in 2004 and only a few years later European 
regulatory approval was obtained by MagForce® for magnetic hyperthermia based 
brain tumour treatment. Since then, many in vivo studies using animal models and 
even clinical trials have been carried out to study the possible application of magnetic 
hyperthermia in different cancer types. 
Most of the current research on magnetic hyperthermia is focussed on improving the 
effectiveness of a nanoparticle system to generate heat under an AMF. This parameter 
is most commonly defined by the specific adsorption rate (SAR), the rate at which the 
electromagnetic energy is absorbed, and is highly dependent on the magnetic 
properties, size143 and morphology of the nanoparticles. 143 With the aim of improving 
the heating efficiency different strategies such as the introduction of doping metal 
ions,144–146 core/shell147 structures and the synthesis of non spherical 
nanoconstructs148–150 can be adopted. Nemati et al. for instance recently described 
how a core/shell morphology can enhance the heat generation efficacy of IONPs 
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compared to normal spherical nanoparticles of a similar size.147 Several examples of 
doped compositions and anisotropic structures such as cubes,151,152 octopods,153 
rods,154 or prisms150 and have also been reported over the past few years.  Samia and 
co-workers recently published a thorough study comparing the SAR of spherical and 
cubic IONP as well as the effect of a zinc doped composition in both cases. As shown in 
Figure 30 the Zn-doped oxide nanocubes proved to be the most efficient heat 
producers, with a 5-fold improvement compared to undoped spherical IONPs.152 
Kanaras and co-workers on the other hand reported the application of manganese 
doped iron oxide nanoclusters for both MRI and magnetic hyperthermia.146 Due to 
both the presence of manganese and the cluster structure, the authors achieved a 
greatly improved SAR compared to previously reported manganese ferrite NPs and 
more importantly within a safe amplitude and frequency range of the magnetic field. 
 
Figure 30. (A) TEM images of the Zn-doped and undoped spherical and cubic IONPs 
and (B) the calculated specific absorption rates (SAR) from hyperthermia 
measurements of all samples. Adapted from 152 
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1.3 Theranostic nanomedicine for cancer 
Nanotechnology offers unique opportunities towards improving cancer 
treatment and diagnosis. As described throughout this chapter, nanoparticles do not 
simply play a major role in anticancer drug delivery but can also serve as multimodal 
imaging platforms and even provide additional therapeutic strategies based on their 
intrinsic properties. The possibility of integrating all of these aspects within a single 
platform gave rise to the term “theranostics”, first described by Warner in 2004.155 
Hence, theranostic nanomedicine refers to the integration of diagnostic and 
therapeutic tools in a single entity, in this case, a nanoparticle. 
The research interest in theranostic nanomedicine for cancer has experienced an 
enormous development over the past decade, owing to the advances in both the 
synthesis and functionalization of nanoparticles and their applicability in diverse 
aspects of cancer diagnosis and treatment. One relatively early example of this type of 
system was reported by Medarova et al. in 2007, describing the preparation of 
multifunctional IONPs for the simultaneous targeted delivery and imaging of siRNA 
(Figure 31).156 The incorporation of a NIR dye provided dual optical/MR imaging 
capabilities to monitor the in vivo antitumour therapeutic efficacy of the siRNA.  
 
Figure 31. Schematic representation of the theranostic nanoplatform reported by 
Medarova et al. with the in vivo MRI (right side top) and NIR fluorescence (right side 
bottom) images of the treated tumour bearing mice and the effective silencing of 
survidin achieved with the delivery of siRNA.  
Chapter 1   
 
48 
Over the last few years many more reports and review articles discussing the 
fundamental notions of theranostic nanosystems have been published, which 
integrate different combinations of nanoparticles, drugs, targeting moieties, imaging 
modalities and therapeutic approaches.76,157–159  
Although this thesis is not focused on the design of theranostic nanoparticles, but 
rather on drug delivery, all the systems developed have potential to be used as 
theranostic platforms and may serve as the starting point for the design of more 
advanced systems in the future. 
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1.4 Objectives of the thesis 
Considering the urgent need for safer and more effective therapeutic strategies 
against cancer and the precedents described throughout this chapter, this PhD thesis 
work has mainly focussed on the development of nanoparticle based delivery vehicles 
for anticancer drugs. Taking advantage of the previous work and expertise of the group 
in preparation and functionalization of nanoparticles, the aim of this thesis has been to 
design and prepare different versatile nanocarriers for the delivery and enhancement 
of the chemotherapeutic effect of two specific anticancer agents; a cisplatin platinum 
(IV) prodrug and a immunostimulatory and cytotoxic agent, poly(I:C). 
Although each of the following chapters describes the design, development, 
characterisation and testing of a different nanocarrier-drug system, the common 
objectives of this thesis have been: 
■ The synthesis and characterization of water soluble and biocompatible 
nanoparticle systems with appropriate surface coating for the delivery of the 
chemotherapeutic drugs. 
■ Selecting an appropriate strategy for the incorporation of the anticancer agents 
to each of the nanocarriers based on the possible interactions and the nature 
of each component. 
■ The addition of fluorescent moieties to the system for assessing the cellular 
uptake of the nanoparticles. 
■ Testing the functionality of the drug-loaded constructs in relevant cancer cell 
lines and the potential enhancement of the anticancer properties of the 
selected drugs. 
■ The radiolabelling of the nanoparticles for nuclear image based biodistribution 
studies in tumour bearing mice. 
■ In vivo testing of the therapeutic efficacy of the most promising constructs in a 
relevant mice tumour model. 
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2.1 Introduction 
Prostate cancer as the second most common cancer worldwide1 represents one 
of the leading causes of cancer death in men in western countries. The standard 
treatment is androgen depletion therapy, but despite its initial efficacy, ultimately most 
patients die of disease progression. This is because with time the disease ceases to 
respond and more aggressive and chemotherapy insensitive tumours appear.2 
Therefore there is major need for finding novel molecular targets and alternative 
prostate cancer therapies. 
As described earlier, TLR agonists are part of the toolbox currently being used in cancer 
immunotherapy, as they play a critical role in the early innate immune response. These 
receptors recognize specific molecular motifs (so-called pathogen associated molecular 
patterns (PAMPs)) and trigger signalling cascades that lead to the activation of the 
immune system.3,4 Although TLRs are predominantly expressed in cells of the immune 
system, it has also been reported that various tumour cells from prostate5 and breast 
cancer6 and melanoma7 also express TLR receptors and respond to TLR ligands. Of 
particular interest in this work is the TLR3 receptor, located in the endosomal 
membranes of cells. TLR3 not only recognizes viral RNA as PAMP, but also synthetic 
analogues of double stranded RNA (dsRNA).  
 
Figure 1. Chemical structure of poly(I:C) 
Among synthetic dsRNA analogues polyinosinic:polycytidylic acid (poly(I:C)) (Figure 1) 
stands as a very promising TLR3 agonist for the development of vaccines.8 Even though 
its application in immunotherapy has been studied for many years,8–12 it is only 
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recently that reports show that it can provide a two-pronged mode of action against 
cancer due to having both direct immunogenic and anticancer properties.13–15 
Recognized not only by TLR3 receptors but also by retinoic acid inducible gene I (RIG-I) 
like receptors and melanoma differentiation-associated gene 5 (MDA-5), poly(I:C) can 
specifically activate the innate immune system by stimulating a type I interferon 
response, and also induce direct cancer cell death through different apoptosis-
mediated mechanisms.13,16 This versatility has prompted a great interest in the use of 
poly(I:C) as an anticancer agent against different solid17,18 and even metastatic19 
tumours, and consequently in the development of effective vehicles for its targeted 
delivery. 
Traditional delivery vectors for nucleic acids can be broadly classified as viral and non-
viral; whilst viral vectors are known to be highly efficient they also suffer from major 
drawbacks such as immunogenicity and cytotoxicity. Able to overcome 
immunotoxicity, the research on non-viral vectors has seen a significant increase over 
the last decade. Several chemical carriers have been reported for nucleic acid 
transfection, including liposomes, dendrimers or polymers but among them, 
polyethyleneimines (PEIs) have become a “gold standard”. Characterized by a high 
density of amino groups, these synthetic cationic polymers promote an efficient 
internalization, trafficking and release of nucleic acids within cells (Figure 2).20,21 
 
Figure 2. Generic structure of a branched PEI polymer and schematic representation of 
the transfection mechanism; endocytic internalization of the polyplex structure 
followed by endosomal escape and free trafficking of the cargo to the nucleus. 
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PEIs are able to condense nucleic acid molecules into polyplex structures through 
interactions between the positively charged polymer and the negatively charged 
phosphate backbone of DNA or RNA. Moreover, the highly positive charge density 
provided by the polymer allows not only a rapid internalization of the polyplex 
structure but also a proton-sponge effect mediated endosomal escape.22 The main 
disadvantage of using PEIs as delivery vectors comes from their toxicity, as both the 
transfection efficacy and toxicity are highly dependent on their molecular weight 
(MW).23 
Nanoparticle-based delivery vehicles have emerged as a promising alternative 
to traditional non-viral delivery vectors for nucleic acids. To achieve an effective but 
also safe transfection, many groups have developed nanoparticle based strategies for 
synthetic and natural nucleic acid fragments including the aforementioned poly(I:C). 
For example, targeting improved immune responses Cobaleda-Siles et al. took 
advantage of superparamagnetic iron oxide nanoparticles to selectively deliver 
poly(I:C) via the lymphatic system.24 In this system, the incorporation of the poly(I:C) 
was achieved via non-covalent interactions with water soluble PEGylated IONP 
micelles, which greatly enhanced the immunostimulatory activity of the dsRNA both in 
vitro and in vivo. Moreover, 99mTc radiolabelling and a rhodamine labelled-PEG were 
introduced to enable multimodal imaging of drug delivery (Figure 3). 
 
Figure 3. Structure of poly(I:C) and schematic representation of the poly(I:C) loaded 
IONP-micelles for the intracellular delivery and immune system activation and in vivo 
lymphatic trafficking. 
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Other groups have used silica based nanoparticles as delivery vehicles.  For example, 
Colapicchioni et al. have recently reported a liposome-silica NP hybrid structure25 and 
Ultimo et al. mesoposous silica nanoparticles26 that take advantage of the direct 
antitumour efficacy of the poly(I:C) to kill different tumour cells. Colapicchioni et al. 
tested both PEGylated and non-PEGylated liposome-silica NPs in prostate cancer cells 
(PC-3) and cisplatin resistant breast cancer cells (MCF-7) and found a clear increase in 
the cancer cell killing ability of the nanoparticle mediated poly(I:C). Ultimo et al. on the 
other hand tested the mesoporous silica nanoparticle-poly(I:C) system in TLR3 
expressing breast cancer cells (SK-BR-3), where the use of a porous nanocarrier also 
allows the encapsulation of an additional drug, doxorubicin in this case, prior to the 
functionalization with the poly(I:C). A TLR3 mediated internalization of the 
nanoparticles leads to an increased cytotoxicity in both the single and the dual drug 
loaded systems compared to poly(I:C) alone. 
Finally, a very recent example by Ramani et al. made use of naked zinc oxide 
nanoparticles to deliver poly(I:C) and demonstrated its in vivo efficacy in a murine 
tumour model of melanoma. This system is based on the direct attachment of the 
dsRNA to the surface of intrinsically therapeutic ZnO nanoparticles.27 In such way, the 
anticancer activity of the vehicle itself and the poly(I:C) could contribute to the efficacy 
of the treatment.  
AuNPs have also been used as non-viral gene carriers.28–30 The growing interest in the 
development of AuNP-based delivery vehicles is due to their relatively facile synthesis 
and functionalization, excellent biocompatibility and applicability for therapy and 
imaging. Although a wide range of surface coatings that have been described for 
AuNPs, the possibility of using positively charged polymers, such as PEIs, already 
known to promote an efficient transfection is a particularly interesting approach. 
Combining the ability of PEI to interact with nucleic acids with the unique advantages 
and features provided by AuNPs allows the development of multifunctional delivery 
vectors for nucleic acids. One of the first examples was reported in 2003 by Thomas et 
al. who improved the efficacy of both 2 kDa and 25 kDa PEIs to deliver plasmid DNA to 
mammalian cells by conjugating them to AuNPs.31 Since then several more examples 
have been published for PEIs of different MWs and the delivery of both plasmid DNA 
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and siRNAs to diverse cells.32–37 Song et al. for instance followed a one-pot synthetic 
procedure to prepare 25 kDa PEI-coated AuNPs (Figure 4), which then were able to 
enhance the intracellular delivery of a siRNA into breast cancer cells.34  
 
Figure 4. Characterization of the PEI-capped AuNPs by Song et al.; TEM image (scale 
bar 20nm), UV-Vis absorption spectrum, hydrodynamic size and zeta potential. 
Given the known cytotoxic nature of high MW PEIs, the design of a similar 
system based on less toxic LMW PEI represents a very interesting challenge; therefore 
this chapter will focus on the development of a non-toxic LMW PEI-coated AuNP 
system for the efficient delivery of poly(I:C) as chemotherapeutic agent against 
prostate cancer cells. 
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2.2 Results and Discussion  
2.2.1 Synthesis and characterization of PEI-coated AuNPs 
The main synthetic approach for the preparation of AuNPs consists of the 
chemical reduction of a gold salt, typically gold tetrachloroaurate (HAuCl4), in the 
presence of a stabilizing agent. The tendency of gold colloids to aggregate in solution 
make the use of capping ligands essential to control the particle size and stability of 
AuNPs.38 Cationic polymers like PEIs should make excellent protective ligands as they 
can stabilize the nanoparticles by a combination of both steric and electrostatic 
effects.39 Moreover, it has been described that polyamines can not only act as 
protective agents but also are able to reduce the gold salt and form stable colloids 
without the need of an additional reducing agent.40 Hence, using PEI as both stabilizing 
and reducing agent for the preparation of AuNPs allows a facile single-step preparation 
of water soluble nanoparticles. Control over the AuNP size can potentially be achieved 
by systematically varying the initial molar ratio between both components.  
PEIs are available in a wide range of molecular weights (MW) and with both linear and 
branched topologies. In general high MW PEIs have improved transfection efficiency 
but also show greater toxicity.23 With the aim of keeping the toxicity as low as possible 
and the incorporation of the AuNP, this thesis work focused on using a non-toxic low 
MW (1.8 kDa). The PEI-coated AuNPs (PEI-AuNPs) were prepared by slightly modifying 
a previously reported synthesis, where high MW PEI was used.34,41 The procedure 
allowed the rapid preparation of water soluble AuNPs in a single step by incubating the 
PEI with an aqueous solution of HAuCl4 at 90 ºC for 2 h. 
 
Scheme 1. One-pot synthesis of LMW PEI-coated AuNPs. 
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The formation of the AuNPs was monitored by recording the UV-vis absorption spectra 
of the reaction mixture at different time points. As it can be seen in Figure 5, the 
absorption band corresponding to the unreacted tetrachloroaurate salt (310 nm) 
initially red-shifts when the PEI is added, and as the reaction progresses the plasmon 
band indicating the formation of the AuNPs starts to develop at ca. 520 nm and 
continues to gain intensity until it reaches saturation after 2 h. It is at this point that 
the reaction is left to cool and the mixture is purified to remove excess reactants, 
rendering a stable aqueous solution of PEI-AuNPs. 
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Figure 5. UV-vis spectra of the solutions of HAuCl4 and 1.8 kDa PEI at different stages 
of the synthesis of the PEI-capped AuNPs in water. 
 After purification, the PEI-AuNPs were characterized to determine the size, 
morphology and polydispersity (Figure 6). Transmission electron microscopy (TEM) 
images show non-aggregated spherical AuNPs with a core diameter of 10.3 ± 1.5 nm. 
These results are consistent with the dynamic light scattering (DLS) measurements of 
the aqueous solution that indicate an average hydrodynamic diameter of 14.7 ± 0.2 nm 
with a relatively narrow size distribution (poly dispersity index (PdI) = 0.072 ± 0.008). 
As expected for spherical AuNPs of this size42 the UV-vis spectrum of the solution 
shows an intense absorption band at 521 nm assignable to surface plasmon resonance. 
Finally, zeta potential studies confirmed the presence of the positively charged PEI on 
the surface of the AuNPs (zeta potential = 28.4 ± 2.0 mV).  
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Figure 6. Characterization of PEI-AuNPs. (A) Representative TEM images and (B) size 
distribution histogram indicating an average diameter of 10.3 ± 1.5nm. (C) 
Hydrodynamic diameter and (D) UV-vis spectrum showing the surface plasmon 
resonance band at 521 nm. 
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 A fluorescently labelled analogue of PEI-AuNPs was also synthesized for flow 
cytometry and fluorescence microscopy studies. As summarized in Scheme 2, the 
incorporation of the fluorophore was achieved by attaching it to the PEI prior to the 
preparation of the nanoparticles. The same LMW PEI used in the non-fluorescent PEI-
AuNP preparations was employed for the labelling as well. The attachment of 
rhodamine B was achieved using standard carbodiimide chemistry (EDC/NHS) adapting 
a previously reported protocol.43 After this coupling reaction, the modified PEI was 
used to prepare the rhodamine-labelled PEI-AuNPs as described above. The free PEI 
and/or fluorophore were removed in the purification step. 
 
Scheme 2. Schematics of the incorporation of rhodamine B to the PEI and synthesis of 
rhodamine-labelled PEI-AuNPs. 
The purified system was characterized by TEM, confirming that the morphology of the 
nanoparticles had not been altered by the incorporation of the fluorophore (Figure 7). 
Due to overlapping between the absorption band of rhodamine B and the plasmon 
band of the AuNPs the UV-vis absorption spectrum of the rhodamine-labelled PEI-
AuNPs (Figure 8) was very similar to that of the PEI-AuNPs. The fluorescence spectrum 
on the other hand showed the distinct red emission peak due to the presence of 
rhodamine B, confirming the formation of Rho-PEI-AuNPs.  
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Figure 7. TEM images of the rhodamine-labelled PEI-AuNPs at different magnifications. 
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Figure 8. UV-vis absorption (continuous line) and fluorescence spectra (dashed line) of 
the rhodamine-labelled PEI-AuNPs. 
2.2.2 Delivery of poly(I:C) 
 The incorporation of poly(I:C) was achieved by electrostatic interaction 
between the positively charged PEI on the surface of the nanoparticles and the 
negatively charged phosphate backbone of the dsRNA. For the preparation of PEI-
AuNPs-poly(I:C) complexes, aqueous solutions of PEI-AuNPs and poly(I:C) were mixed 
and incubated for ca. 15 min at room temperature. The characterization of the 
poly(I:C) containing systems (Figure 9) reflects that the incorporation of the dsRNA 
does not significantly affect neither the size nor the morphology of the AuNPs. It is 
however clear from the zeta potential measurements that the association takes place 
(i.e. the surface charge became less positive after the addition of poly(I:C)) changing 
from 28.4 ± 2.0 mV to 18.1 ± 0.1 mV in samples with 100 µM Au and 1 µg/mL poly(I:C). 
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Figure 9. Hydrodynamic diameters of PEI-AuNPs (continuous line) and PEI-AuNPs-
poly(I:C) (dashed line) at 100 µM Au and 1 µg/mL poly(I:C) in aqueous solution. 
2.2.3 Cell culture studies 
 To test the cancer cell killing ability of the PEI-AuNP-poly(I:C) system, a highly 
aggressive human prostate cancer cell line PC-3 was selected. As described in the 
introduction, TLRs are not only expressed in cells of the immune system but also in 
many cancer cells. The expression of TLR3 in PC-3 cells was confirmed by flow 
cytometry (Figure 10). 
 
Figure 10. Flow cytometry histogram of TLR3 positive PC-3 cells (continuous line), 
negative control (dashed line) and non-labelled cells (grey peak). 
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2.2.3.1 Cellular uptake 
 The uptake and intracellular fate of the Rho-PEI-AuNPs in PC-3 cells was studied 
by flow cytometry and fluorescence microscopy. Following a 2 h of incubation with the 
Rho-PEI-AuNPs, flow cytometry analysis confirmed the uptake of the fluorescent 
nanoparticles by PC-3 cells. Live cell fluorescence microscopy showed the presence of 
the labelled system (red fluorescence) within the cytoplasm region of the cells (Figure 
11). Then, a commercially available fluorescently labelled poly(I:C) allowed the 
preparation of a dual-labelled system to allow for the independent tracking of the 
nanoparticle delivery vehicle and its cargo. (Scheme 3)  
 
Figure 11. (A) Flow cytometry histogram of PC-3 cells incubated with Rho-PEI-AuNPs 
for 2 h (B) fluorescence microscopy image taken of live PC-3 cells after 2 h incubation 
with Rho-PEI-AuNPs (red). The nuclei are stained with Hoechst 33342 (blue). 
 
Scheme 3. Schematics of the rhodamine-labelled PEI-AuNP system conjugated with the 
FITC-labelled poly(I:C) used for fluorescence microscopy. 
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The fluorescence microscopy images of the dual-labelled system confirm the uptake of 
both the PEI-AuNP (shown in red) and the poly(I:C) (shown in green) after 2 h (Figure 
12). Higher magnification images clearly show that although both components are 
successfully internalized, they separate and follow a different fate (Figure 13). 
 
Figure 12. Fluorescence microscopy images taken of live PC-3 cells after 2 h incubation 
with Rho-PEI-AuNP (Red) - FITC-poly(I:C) (green) at 2 µg/mL poly(I:C). Nuclei are 
stained with Hoechst 33342 (blue).  
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Figure 13. Uptake and trafficking of the Rho-PEI-AuNP (red) - FITC-poly(I:C) (green) 
system in PC-3 cells after 2 h of incubation at 2 µg/mL poly(I:C). Nuclei were stained 
with Hoechst 33342 (blue), PEI-AuNPs were labelled with Rhodamine B (red) and 
commercially available FITC labelled poly(I:C) (green) was used. 
Fluorescence microscopy also show that, after 2 h incubation, in the absence of 
nanoparticle, no uptake of poly(I:C) was detectable; even after 24 h only weak green 
fluorescence was detected in the cells. Flow cytometry was used to corroborate these 
results and obtain more quantitative data. Figure 14 shows that after 2 h incubation 
only shift in fluorescence intensity between negative control and positive samples is 
obtained when poly(I:C) is combined with the PEI-AuNP vehicles. 
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Figure 14. Flow cytometry histogram of PC-3 cells incubated with PEI-AuNP/FITC-
poly(I:C) (red) or FITC-poly(I:C) (green) for 2 h at  5 µg/mL poly(I:C) concentration. 
2.2.3.2 Cancer cell killing efficacy 
The cytotoxicity of the PEI-AuNPs in PC-3 cells was studied first. Cell viability 
was determined using the MTT assay, and the results showed that almost 100% cell 
viability is retained up to 10 µM of gold even after 72 h incubation with the PEI-AuNPs 
(Figure 15); therefore this was the concentration selected for the poly(I:C) delivery 
studies.  
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Figure 15. Cytotoxicity profile of PEI-AuNPs in PC-3 cells after 72 h incubation. Au(0) 
concentrations are determined from the UV-Vis spectrum. 
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To test the cancer cell killing ability of the PEI-AuNP-poly(I:C), a fixed PEI-AuNP 
concentration (10 µM gold) and three different poly(I:C) (referred as pIC in the figures 
below) concentrations were selected to explore the effect using different poly(I:C) to 
nanoparticle ratios. In all cases, the free poly(I:C) presents negligible in vitro 
cytotoxicity. When is delivered by PEI-AuNPs however, the results show that the cell-
killing ability is significantly enhanced at the lowest poly(I:C) concentration (0.1 µg/mL) 
(Figure 16). In contrast increasing concentrations of poly(I:C) lead to less efficient 
systems for cancer cell killing. A possible explanation for this observation is that 
increasing amounts of poly(I:C) provide systems that have a more free poly(I:C)-like 
nature, therefore masking the effect of the delivery vehicle. Nevertheless, we note 
that even the less cytotoxic systems may show improved in vivo therapeutic efficacy if 
the PEI-AuNPs provide improved delivery to the tumour. 
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Figure 16. Cytotoxicity of free poly(I:C) and PEI-AuNPs-poly(I:C) in PC-3 cells after 72 h. 
[poly(I:C)] stated in X-axis; [Au(0)] = 10 µM in all cases. 
To investigate the importance of the nanoparticle as drug delivery vehicle, the effect of 
using free PEI was also evaluated given its known ability to act as a transfection agent 
by itself. A range of PEI to poly(I:C) ratios were studied but in terms of cell viability 
none of these systems shows any significant difference compared to the free PEI 
(Figure 17). Hence, the AuNPs are critical for more effective delivery and cytotoxic 
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effect of the poly(I:C). This observation is supported by several studies that show the 
enhanced ability of large DNA molecules to wrap around the curved surface of the 
nanoparticles through a combination of hydrophobic and electrostatic interactions. 
Thus the “pre-arranged” curved conformation provided by the PEI-AuNPs might favour 
the interaction, resulting in a more effective delivery of poly(I:C) to the cells that 
cannot be achieved with the LMW PEI on its own. 
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Figure 17. Cytotoxicity of PEI (white circles) and PEI-poly(I:C) at two different poly(I:C) 
concentrations, 0.1 µg/mL (blue circles) and 1 µg/mL (red circles) in PC-3 cells. 
 Regarding the possible mechanism behind the cancer cell death, Besch et al. 
already reported that poly(I:C) causes the activation of apoptotic mechanisms 
mediated not only by TLR-3, but also RIG-I and MDA-5 receptors.44 To determine if the 
decrease in cell viability involves an apoptotic pathway, PC-3 cells treated with 
poly(I:C), PEI-poly(I:C), PEI-AuNP-poly(I:C) and their corresponding controls were 
stained with a commercially available Annexin V apoptosis kit an analyzed by flow 
cytometry. These experiments showed that the main population in all the controls as 
well as for the PEI-poly(I:C) system was made up of live cells (Figure 18). However, the 
cells treated with the PEI-AuNP-poly(I:C) had an increased population of both 
apoptotic and late apoptotic/necrotic cells. This indicates that the cancer cell killing 
effect of poly(I:C) delivered with PEI-AuNPs indeed occurs through an apoptosis 
mediated mechanism. 
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Figure 18. Apoptosis quantification by Annexin V staining in PC-3 cells treated with 
poly(I:C), PEI, PEI-poly(I:C), PEI-AuNPs and PEI-AuNPs-poly(I:C) in PC-3 cells after 72 h. 
[poly(I:C)] = 0.1 µg/mL, [PEI] = 1 µM, [Au(0)] = 10 µM.  
 Even though several different systems with poly(I:C) have already been 
reported to cause cancer cell death,25,45 the PEI-AuNP based delivery has not only 
proved to be effective but more importantly the effect is most pronounced at very low 
doses of poly(I:C). Next, the potential synergy between the PEI-AuNP and a recently 
developed peptide-based transfection agent (P21-LK15-8R)46 to enhance the cancer 
cell killing activity poly(I:C) was evaluated. This peptide-based structure developed by 
Gibson et al. at the University of Nottingham was selected because it has already 
demonstrated a significant nucleic acid transfection efficacy. The peptide consists of 
three components, a short 21-residue peptide (p21), a nucleic acid interaction 
sequence (LK15) and an 8R sequence. The transfection efficiency of this system is not 
only comparable to that of the commercial transfection agent Lipofectamine 2000 but 
most importantly (and unlike Lipofectamine 2000), it is retained even in serum 
containing environments.  
The cytotoxicity of poly(I:C) was examined with the peptide alone and with the 
combination of both the peptide and the PEI-AuNP. As shown in Figure 19, the 
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addition of the P21-LK15-8R to the poly(I:C) resulted in a concentration dependent 
decrease in viability, the opposite behaviour to that observed with the PEI-AuNP. 
When both transfection systems are used together, although a slightly more cytotoxic 
effect could be observed at 1 µg/mL, the viability pattern was similar to that of 
poly(I:C)-P21. This result suggests that rather than interacting in a synergistic way, 
both components compete and most of the effect due to the PEI-AuNP is presumably 
inhibited by the formation of stronger P21-LK15-8R/poly (I:C) complexes. Nevertheless, 
it is important to note that even though P21-LK15-8B is able to act as an efficient 
transfection agent for poly(I:C) and enhance cancer cell killing, the PEI-AuNP delivery 
system achieved a similar toxicity with 10-fold less poly(I:C). 
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Figure 19. Cytotoxicity of free poly(I:C), combined with P21-LK15-8R at  1 µM and with 
both P21-LK15-8R and PEI-AuNP ([Au] = 10 µM) in PC-3 cells. Poly(I:C) concentrations 
shown on the X-axis. 
 Since poly(I:C) is mainly used as an immunomodulatory agent in 
immunotherapy, we evaluated next the effect of the PEI-AuNP delivery system 
towards poly(I:C)-induced the activation of cells of the immune system. For this 
purpose, the PEI-AuNP-poly(I:C) system was incubated with J774 murine macrophages, 
and both cytotoxicity and cytokine production were examined. The presence of PEI-
AuNPs does induce any significant changes on neither the cytotoxicity nor the 
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immunostimulatory activity of poly(I:C) in terms of IL-6 cytokine production (Figure 
20).  Moreover, the poly(I:C) concentration that in combination with PEI-AuNPs led to 
a significant increase in cancer cell killing ability (0.1 µg/mL) did not induced IL-6 
production or cytotoxicity in macrophages. 
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Figure 20. (A) Cell viability of free poly(I:C), PEI-AuNP-poly(I:C) and the corresponding 
PEI-AuNP control ([Au] = 10 µM) in J774 murine macrophages. (B) IL-6 cytokine 
production of J774 macrophages treated with the aforementioned formulations. 
To establish the uniqueness of this AuNP based construct to promote cancer 
cell death, a comparative study was done using PEGylated IONP micelles to deliver 
poly(I:C) to both PC-3 cancer cells and J774 macrophage cells. These PEGylated 
micelles were selected because they have already been reported as effective delivery 
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system for poly(I:C) for enhancing immunostimulatory properties and their size and 
morphology is similar to that of the PEI-AuNPs.  
Summarized in Figure 21 and Figure 22, the results showed that the change of delivery 
vehicle leads to a totally different behaviour of poly(I:C) in terms of both cytotoxicity 
and immunostimulatory activity. In the case of PC-3 cells (Figure 21), when the 
poly(I:C) was delivered with IONPs there is no cytotoxic effect, the cell viability 
remained constant to that of the IONP itself. Upon the addition of P21-LK15-8R the 
viability decreased in a concentration dependent manner and was more effective than 
using P21-LK15-8R alone at the lowest poly(I:C) concentration (0.1 µg/mL)  peptide.  
The results in the macrophage cell line were similar to those reported by Cobaleda et 
al.24 None of the formulations shows any major reduction in cell viability, but the IL-6 
cytokine production is drastically improved with the IONP-poly(I:C) system. The 
addition of P21-LK15-8R however did not improve the enhancement produces by the 
nanoparticle; while a similar cytokine production can be observed for the highest 
poly(I:C) concentration (25 µg/mL), the IONP alone is more effective in enhancing the 
immunostimulatory activity of poly(I:C) at lower concentrations. 
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Figure 21. Cytotoxicity of poly(I:C) at 10 µg/mL, 1 µg/mL and 0.1 µg/mL, combined with 
IONP ([Fe] = 100 µM) and with both P21-LK15-8R (1 µM) and IONP ([Fe] = 100 µM) in 
PC-3 cells. 
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Figure 22. (A) Cytotoxicty of poly(I:C) at 25 µg/mL, 12.5 µg/mL and 6.25 µg/mL and in 
combination with IONP ([Fe] = 100 µM) and both P21-LK15-8R (1 µM) and IONP ([Fe] = 
100 µM) in J774 murine macrophages. (B) IL-6 cytokine production of J774 
macrophages treated with the aforementioned formulations. 
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2.3 Conclusions 
In summary, this chapter describes the facile single-step synthesis and 
characterization of PEI-coated AuNPs, which due to the positively charged surface 
provided by the polymer are able to electrostatically interact with the TLR3 agonist 
poly(I:C) and promote its delivery into prostate cancer cells. The nanocarrier has not 
only demonstrated to increase the uptake of poly(I:C) in PC-3 cancer cells but also to 
selectively promote a chemotherapeutic effect (providing enhanced cancer cell killing 
ability to poly (I:C)  rather than enhanced immunostimulation as found in recently 
reported IONP carriers developed in the group.  
In view of the results obtained from the comparative study between the PEI-AuNPs 
and PEGylated IONP micelles for the delivery of poly(I:C), it becomes clear that 
poly(I:C) can indeed provide a two-pronged mode of action against cancer, namely 
chemotherapy and immunotherapy, where any one of them can be selectively 
enhanced via careful selection of nanoparticles carriers. The specific change of 
behaviour could be related to the nanocarriers coating or composition causing 
poly(I:C) to interact differently; such changes may result in poly(I:C) being recognized 
by different cells and/or receptors that ultimately lead to either immunostimulatory or 
cytotoxic mechanisms.  
The use of a simple and easy to prepare construct such as these PEI coated AuNPs as 
vehicles for poly(I:C) not only proved to be a new and an effective approach from the 
delivery point of view, but more importantly this particular system has demonstrated it 
affects the intracellular behaviour of poly(I:C), selectively enhancing its cancer cell 
killing ability. Although not investigated, by using this system it may be possible to use 
the intrinsic properties of AuNPs for both imaging and PTT, opening up a whole range 
of new possibilities for the further development of more sophisticated PEI-AuNP based 
theranostic nanoplatforms for simultaneous cancer imaging and therapy. 
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2.4 Experimental Section 
2.4.1 Materials. 
  All syntheses were carried out with the following commercially available 
reagents used without further purification. Hydrogen tetrachloroaurate(III) trihydrate 
(99.99%) and polyethyleneimine (branched, 1.8 kDa, 99%; 36% NH2, 29% NH and 35% 
N determined by NMR studies) were purchased from Alfa Aesar. Rhodamine B (≥ 95%), 
N-hydroxysuccinimide (98%), sulforhodamine B sodium salt and trichloroacetic acid (> 
99%) were purchased from Sigma Aldrich. 1-Ethyl-3-[3-dimethylamino 
porpyl]carbodiimide hydrochloride (EDC) was purchased from Thermo Scientific. 
Poly(I:C) and poly(I:C)-fluorescein were purchased from Invivogen. BD 
Cytofix/Cytoperm™ Plus Fixation/Permeabilization Kit and Fc blocking antibody were 
purchased from BD Biosciences. Anti-TL3 and AlexaFluor488 antibodies were 
purchased from Abcam. Annexin V/Dead Cell Apoptosis Kit was purchased from 
Invitrogen. 
2.4.2 Synthesis of PEI-coated AuNPs 
To prepare the PEI-coated AuNPs, PEI dissolved in water was added to an 
aqueous solution of HAuCl4 in a 2:1 molar ratio and the mixture was stirred at 90 ºC. 
This preparation is slightly modified from recent literature preparation, which used 
high molecular weight PEI.34,41 In this study PEI-coated AuNPs formed after 2 h were 
used. Once the reaction mixture was cooled to room temperature, the PEI-AuNPs were 
purified by passing through a centrifugal filter unit (MWCO 50000; Amicon Ultra-4). 
2.4.3 Synthesis of rhodamine-labelled PEI and rhodamine labelled PEI-
AuNPs 
Rhodamine-labelled PEI was prepared adapting a previously described protocol 
used for the preparation of fluorescein-labelled PEI.43 N-hydroxysuccinimide (NHS) (23 
mg, 0.2 mmol) and N-(3-dimethylaminopropyl)-N’-ethycarbodiimide hydrochloride 
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(EDC) (38mg, 0.2mmol) were dissolved in PBS 10 mM pH 6 and stirred for 15 minutes 
at room temperature. Rhodamine B (4.8 mg, 10 µmol) was added and left to react with 
magnetic stirring for 2 h at room temperature. Finally an aqueous PEI solution (120 µL, 
5 mg/mL) was added to the mixture and allowed to react under magnetic stirring for 2 
h at room temperature. Rhodamine labelled PEI-AuNPs were prepared as above using 
the rhodamine labelled PEI accordingly diluted in water. Any unbound rhodamine B 
was later removed in the purification step.  
2.4.4 Sample preparation 
  All samples were freshly prepared simply by mixing an aqueous solution of 
poly(I:C) at the appropriate concentrations with an aqueous solution of PEI or PEI-
coated AuNP (concentrations given in the figure captions). For the cell culturing 
experiments, prior to the incubation with the cancer cells, the samples were left to 
interact for ca. 30 minutes and then were diluted 1/10 in cell culture medium and 
directly added to the cells to ensure no loss of reagents. In the studies with PEI-AuNPs, 
the gold concentration refers to Au(0) determined from the UV-Vis spectrum of the 
nanoparticle stock solution once purified to remove any excess of reagents. This Au(0) 
concentration can be directly correlated to the absorbance value at 400 nm.47 
2.4.5 Cell culture experiments 
  PC-3 human prostate cancer cell line was obtained from the American Type 
Tissue Collection (ATCC) and cultured in Ham’s F-12K (Kaighn’s) medium (Glibco) 
supplemented with 10% foetal bovine serum (Invitrogen) at 37 ºC under 5% CO2. Cells 
were passaged at ~ 70% confluence and a low passage number was maintained using 
cryopreserved stocks stored in foetal bovine serum supplemented with 10% DMSO. 
TLR3 expression. PC-3 cells were trypsinized, resuspended FACS buffer and 
transferred to cytometry tubes (5·105 cells/tube in 100 µL). Fc receptors were blocked 
for 10 min at 4 ºC. Cells were fixed and permeabilized for 15 min using a BD 
Cytofix/Cytoperm fixation and permeabilization kit at 4 ºC. After being washed with BD 
Perm/wash buffer cells were incubated at 4 ºC for 20 min with the primary anti-TLR3 
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antibody (10 µg/mL). Cells were then washed with BD Perm/wash buffer and Alexa 
Fluor 488-labelled secondary antibody (1 µg/mL) was used for staining the primary 
TLR3 antibody for 30 min at R.T. Finally cells were washed tree times with BD 
Perm/wash buffer and resuspended in FACS buffer for flow cytometry analysis. 
Cell viability studies. Cells were plated at a 3000 cell/well density in 96-well plates 
and allowed to adhere overnight. All samples were freshly prepared and diluted 1/10 
in medium before incubating at 37 ºC using 200 µL of sample per well in triplicate. The 
cell viability was measured using the sulforhodamine B assay.48 To determine the 
viability after 72 h, the cells were fixed by the addition of ice cold 25% trichloroacetic 
acid (TCA) solution prior to staining with the sulforhodamine dye (SRB) solution (0.4% 
w/v in 1% glacial acetic acid). The plates were washed with 1% glacial acetic acid, air 
dried and resuspended in Tris buffer (10 mM, pH 10.5) before reading the absorbance 
at 550 nm. 
Cell imaging. For the live cell microscopy, PC-3 cells were seeded in an Ibidi 18 well 
µ-Slide at 4000 cell/well density and allowed to adhere overnight in an incubator (37 
ºC, 5% CO2) in Ham’s F-12K (Kaighn’s) medium. The medium was changed and the 
nuclei stained with Hoechst 33342 (5 µg/mL) for 5 minutes, washed with sterile PBS 10 
mM and incubated with the rhodamine labelled AuNPs and/or FITC labelled poly(I:C) 
formulations for 2 h. The medium was then removed, cells washed with sterile PBS 10 
mM and fresh medium was added prior to image acquisition.  
Cellular uptake by flow cytometry. PC-3 cells were plated in 96-well plates (105 
cell/well) and allowed to adhere overnight in Ham’s F-12K (Kaighn’s) medium. 
Fluorescent formulations containing rhodamine labelled PEI-AuNPs or FITC-labelled 
poly(I:C) were diluted in medium accordingly and added to the cells for 2 h incubation 
at 37 ºC. After the incubation, the supernatant was removed and cells washed with 
PBS (10 mM). The adherent cells were trypsinized, transferred to cytometer tubes and 
washed with PBS (10 mM). Cells were resuspended in a final volume of 200 µL flow 
cytometry buffer (1% BSA, 0.1% sodium azide in PBS 10 mM) for uptake 
measurements. 
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Apoptosis assay. PC-3 cells were plated at 3000 cell/well density in 96-well plates 
and left to adhere overnight. Cells were then treated with the AuNP-poly(I:C) 
formulations (10 replicates per sample) at the indicated doses for 72 h. After 
treatment, apoptosis was assessed by Annexin V staining according to the 
manufacturer’s instruction. Treated and untreated cells were stained with Pacific Blue 
Annexin V and SYTOX AAdvanced dead cell stain and analyzed by flow cytometry.  
2.4.6 Instrumentation 
TEM. TEM studies were conducted in a JEOL JEM-2011 electron microscope operating 
at 200 kV. The samples were prepared by depositing a drop of nanoparticle solution 
onto a copper specimen grid coated with a holey carbon film and allowing it to dry. For 
nanoparticle size determination a minimum of 300 particles were measured using the 
Image J software. 
UV-Vis and Fluorescence spectroscopy. UV-vis measurements were performed 
in H2O using a Varian Cary 5000 spectrophotometer. Absorbance measurements on 
96-well plates were carried out on a TECAN Genios Pro 96/384 multifunction 
microplate reader. Fluorescence emission spectra were recorded with a Horiba Jovin 
Ibon Fluorolog flurometer. 
DLS and ζ-potential. Particle size analysis was performed using a NanoSizer 
(Malvern Nano-ZS, UK) with 173° scattering angle at 25 ºC. Each sample was measured 
at least in triplicate. Ζ-potential measurements were carried out with the same 
NanoSizer equipment at 25 ºC and a cell drive voltage of 20 V using a Smoluchowski 
model. 
Flow cytometry. All flow cytometry experiments were carried out in a FACS Canto II 
(BD Bioscience) system, which has an excitation source composed of three lasers: 
violet (405 nm), blue (488 nm) and red (633 nm). The laser excitation wavelength used 
for both FITC and rhodamine was 488 nm and the emission filters 530/30 nm and 
585/42 nm respectively. The laser excitation wavelength used for SYTOX was 488 nm 
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and the emission filter 670-735 nm, for Pacific Blue Annexin V the excitation 
wavelength was 405 nm and the emission filter 425-475 nm. In all measurements cells 
were electronically gated based on forward and side scatter parameters and the not-
singlet events leaved out based on forward area and height parameters. Each analysis 
represented the acquisition of 10000 cells per sample and data was analyzed with 
FlowJo LLC software. 
Fluorescence microscopy. Live cell fluorescence images were obtained using Zeiss 
Axio Observer wide field fluorescence microscope (Carl Zeiss, Germany). Both a colibri 
LED module and a mercury short-arc HXP lamp were used for fluorescence excitation: 
365 nm LED excitation for Hoechst staining, 470 nm LED excitation for FITC and HXP 
lamp for rhodamine B.  Fluorescence emission was collected using a high-efficiency 
multi-band pass colibri filter set which included a 402-488 nm bandpass for Hoechst 
and 500-557 nm for FITC; rhodamibe B emission was collected using an emission filter 
with a 570-640 nm bandpass. Brightfield and fluorescence images were collected and 
processed using AxioVision software. 
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3.1 Introduction 
 Cisplatin stands as one of the most commonly used and few chemotherapeutic 
agents with broad efficacy for cancer treatment.1 Despite its clinical success, there are 
several limitations to its use, including limited selectivity, development of side effects 
and resistance mechanisms. In a bid to overcome these issues, a prodrug strategy has 
been adopted in this work, using inert platinum (IV) prodrugs that can be reduced 
inside cancer cells to render cytotoxic species (Scheme 1). 
 
Scheme 1. Prodrug strategy based on the intracellular reduction of inert platinum (IV) 
prodrugs to generate cytotoxic species. 
Although extensive research has already been performed in area of platinum (IV) 
prodrug research,2 there is still much room for improvement regarding the efficient 
delivery and therapeutic efficacy of these compounds. In this regard, apart from the 
targeting and dual action therapeutic strategies mentioned in the introduction, 
nanoparticle delivery platforms have also become a very attractive way of enhancing 
the anticancer efficacy of anticancer platinum prodrugs by providing both active and 
passive targeting and prolonged bloodstream circulation among other advantages.  
Over the past few years several platinum (IV) prodrugs have been attached to 
nanoplatforms to facilitate their delivery and activation. Many types of nanoparticles 
have been employed for this purpose, including carbon nanotubes,3,4 gold 
nanoparticles5 and nanorods,6 polymeric,7–11 silica12 and iron oxide nanoparticles,13,14 
up-converting nanomaterials,15 semiconductor nanocrystals,16,17 copper sulphide18 
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nanoparticles and silk fibroin nanoparticles.19 Lippard and co-workers reported various 
systems based on the encapsulation of a hydrophobic platinum (IV) prodrug in PLGA-
PEG nanospheres, also incorporating targeting moieties such as  prostate specific 
membrane aptamer (PSMA) for prostate cancer or RGD targeting peptides for breast 
cancer (Figure 1). The studies investigating the effectiveness of the delivery system in 
two different prostate cancer cell lines (PC-3 and LNCaP)7 as well as the in vivo efficacy 
in both a LNCaP xenograft mouse model of prostate cancer20 or a highly metastatic 
human breast carcinoma xenograft model,21 show that these PLGA-Pt(IV) nanosystems 
achieve an effect comparable to that of cisplatin but with fewer side effects.  
 
Figure 1. Scheme of the preparation of PMSA aptamer and c(RGDfK) functionalized Pt-
PLGA-PEG nanoparticles. 
The nanoparticle based delivery of hydrophilic platinum (IV) prodrugs has also been 
widely studied over the past decade. One of the first examples was reported by Lin and 
co-workers, who incorporated a succinate derivative platinum (IV) complex into 
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nanoscale coordination polymer nanoparticles formed with Tb3+, and then stabilized 
the system by adding a silica shell as well as a RGD peptide for active targeting (Figure 
2).22 
 
Figure 2. Schematic representation of the formation of platinum loaded nanoscale 
coordination polymer (NCP) nanoparticles and the incorporation of cyclic RGD for 
active targeting. Adapted from 22 
Another common approach is the covalent attachment of the prodrug to the 
nanoparticles; Min et al. and Dai et al. both reported the conjugation of the platinum 
(IV) complex to amine terminated PEG ligands on gold nanorods6 and UCNPs15 
respectively, then achieving the liberation of the drug through the reductive 
elimination of the axial ligands. Chen et al. on the other hand performed a similar 
conjugation strategy using the free amine groups of gelatine-coated IONPs.13 In 
addition to the traditional drug release mechanism based on intracellular reduction, 
Mareque and co-workers reported a photo-induced activation of a platinum (IV) 
prodrug through an electron transfer process using quantum dots.16,17  
While the main strategies used for the nanoparticle based delivery of platinum 
prodrugs are encapsulation and covalent attachment through the axial ligands, this 
work is focused on exploiting the supramolecular chemistry of an anionic platinum 
prodrug to promote outer-sphere interactions with PEI as a novel approach in 
medicinal inorganic chemistry and nanomedicine. The next sections will examine the 
nature of the interactions and how they are applied for the delivery of a platinum (IV) 
prodrug using PEI-coated AuNPs as a novel approach to enhance the therapeutic 
efficacy in different cancer cell lines.  
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3.2 Results and Discussion 
3.2.1 Synthesis and characterization of Pt-complexes 
 Given the importance and growing interest in the development of Pt(IV) 
prodrug based systems, different platinum based complexes have been synthesized for 
investigating their potential use in combination with nanoparticle based drug delivery 
systems. The synthetic procedures employed for the preparation of such complexes 
have already been reported in the literature. 
As it was described by Hall et al., the well known Pt(II) drug cisplatin yields the bis-
hydroxy Pt(IV) complex (3) when subjected to oxidation with hydrogen peroxide.23 
Further treatment of (3) with an excess of succinic anhydride leads to the formation of 
the succinate derivative (1)22 (Scheme 2), a Pt(IV) cisplatin prodrug which can be 
intracellularly reduced back to cytotoxic Pt(II) species.  It is also important to mention 
that while the parent Pt(II) species are mainly soluble in organic solvents, the 
subsequent Pt(IV) complexes and specially (1) have a more hydrophilic nature, making 
them more promising for therapeutic applications. 
 
Scheme 2. Reaction scheme for the synthesis of the cisplatin derived Pt(IV) prodrug 
(1). 
In order to later study the individual contribution of the different ligands around the 
platinum centre in the outer sphere interactions, a different Pt(IV) succinate derivative 
was also synthesized. Starting from another known Pt(II) drug, nedaplatin, a similar 
procedure leads to the formation of the succinate Pt(IV) complex (2) which has a 
glycolate ligand instead of the two chloro groups (Scheme 3).24 
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Scheme 3. Reaction scheme for the synthesis of the nedaplatin derived Pt(IV) prodrug 
(2). 
The 1H NMR spectrum of cisplatin (Figure 3A) shows the characteristic signal belonging 
to the protons of the amino groups appearing at high field. As shown in the 
subsequent spectra, this signal shifts downfield when the platinum centre is oxidized 
to the bis-hydroxo and then converted to the succinate derivative due to the lower 
shielding of these protons in each case. The presence of the hydroxyl ligands on (3) can 
be observed in the 1H spectrum where the broad peak corresponding to these groups 
appears at ca. 10 ppm (Figure 4). The two characteristic triplets arising from the 
succinate ligands on (1) can also be clearly detected in the 1H NMR spectrum (Figure 
5), confirming the presence of the axial ligands in the complex. The chemical shift of 
the triplets from these succinic protons in (1) is also dependent on the pH (Figure 6).  
 
Figure 3. 1H NMR spectra of cisplatin (A), (3) (B) and (1) (C) in 10% D2O in H2O showing 
the amino peaks. 
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Figure 4. 1H NMR spectrum (3) DMSO-d6 and detail of the OH peak (inset). 
 
Figure 5. Structure and 1H NMR spectrum of (1) in 10% D2O in H2O and detail of the 
peaks from the succinic protons (inset). 
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Figure 6. pH dependent variation in the chemical shift of the succinic protons of (1) 
In the case of the nedaplatin succinate Pt(IV) complex (2) the 1H NMR spectrum is 
characterized by the peaks from the succinate ligands and the singlet corresponding to 
the glycolic protons (Figure 7). 
 
Figure 7. Structure and 1H NMR spectrum of (2) in D2O and detail of the peaks from the 
succinic protons (inset). 
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3.2.2 Outer sphere interaction between Pt-complexes and PEI 
 Transition metal complexes can participate in a wide range of outer-sphere or 
second coordination sphere interactions. Although exploiting these interactions is 
becoming increasingly useful in a growing number of fields25–28 it has not been applied 
to develop more efficient platinum-based drugs. 
The previously described platinum (IV) complex (1) was selected because apart from 
being considered a prodrug for the archetypical drug cisplatin, it is stable enough to 
travel through the bloodstream until it reaches a tumour cell without premature 
decomposition.1 Apart from that, it also presents excellent features to participate in 
multiple non-covalent outer-sphere interactions with PEI as all ligands can contribute 
to the outer-sphere interaction (Figure 8). In addition to the two carboxylates that give 
an overall -2 charge at neutral pH to provide strong electrostatic attraction with the 
positively charged PEI polymer, (1) has two cis-chloro ligands which have been shown 
to be excellent hydrogen bond acceptors.29,30 Additionally, the two amines should have 
enhanced acidity to act as hydrogen bond donors through coordination to the high 
valent Pt(IV) centre and N-H●●●Cl-Pt hydrogen bonding.31,32 
 
Figure 8. Structure of PEI and (1) and the plausible supramolecular synthons involved 
in the formation of PEI-(1) outer-sphere complexes.  
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 In order to evaluate the proposed interaction, NMR studies were carried out in 
mixtures of (1) and PEI with or without the presence of a biologically relevant reducing 
agent, ascorbate. 1H NMR spectra of the mixtures were recorded at different pH to 
also determine the stability of the interaction in different conditions. 
Consistent with the postulated mechanism of action of (1) as a prodrug, addition of 
ascorbate results in the appearance of a peak due to free succinic acid in a time-
dependent manner (Figure 9). Notably, the intensity of this peak is higher in the 
presence of PEI. When the pH of the solution is adjusted from pH 3-4 to pH 7, the 
effect of PEI towards promoting the release of succinate is even more pronounced, 
suggesting that the interactions of (1) with PEI are optimum at neutral pH.  
 
Figure 9. Changes in the 1H NMR spectrum of (1) (1 mM) on D2O at pH 3-4 (blue) and 
pH 7 (black) in the presence and absence of PEI (10 µM) and ascorbic acid (10 mM). 
In view of the pKa values reported for branched PEI (4.5 for primary, 6.7 for secondary 
and 11.6 for tertiary amine groups)33 and succinic acid (4.2 and 5.6) it is obvious that at 
pH < 4 PEI and (1) will exist in their fully protonated forms. At these pH values, the 
terminal carboxylates of (1) are protonated, and therefore, the neutral Pt(IV) complex 
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interacts less strongly with the cationic PEI. Moreover, it is reasonable to expect that at 
this pH protonation of the N atoms of the PEI may also be preventing the formation of 
Pt-NH3●●●N hydrogen bonding interactions. In contrast, at pH 7 the succinic acid 
groups of (1) are deprotonated and only a fraction of the N atoms are protonated (ca. 
35%), making feasible the formation of the different synergistic outer-sphere 
interactions. As it can be expected from the release of succinic acid and the “proton 
sponge” properties of PEI, over time the pH of the mixture becomes more acidic (pH 
5.5 at 24 h). Although the ability of PEI to promote the efficient internalization and 
trafficking of drugs by cancer cells is already well known, based on these results PEI as 
delivery vehicle for Pt(IV) prodrugs can also contribute to the redox-activation process. 
To elucidate the oxidation state of the platinum products, XPS measurements 
at the Pt 4f region were performed (Figure 10). The spectrum of (1) presents peaks at 
78.9 ± 0.2 eV (4f5/2) and 75.5 ± 0.2 eV (4f7/2) but after the addition of ascorbate shows 
the progressive appearance of new species being generated, with peaks at 76.4 ± 0.3 
eV (4f5/2) and 73.1 ± 0.3 eV (4f7/2) indistinguishable from those of cisplatin.  
 
Figure 10. XPS spectra showing the Pt 4f region of (1), cisplatin and PEI-(1) outer 
sphere complexes in the presence of ascorbic acid 24 h after mixing in water at pH 7. 
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Notably, the proportion of Pt(II) species calculated from the XPS data is somewhat 
lower than it would correspond compared to the amount of free succinate determined 
by NMR. This results indicate that some succinate can indeed be liberated from (1) 
without reduction. This is an important finding in agreement with recent studies that 
show how although the design of Pt(IV) prodrugs is based on the assumption that the 
cytotoxic Pt(II) drug is obtained by clean loss of the two axial ligands, these 
assumptions need to be reassessed as other products can also be formed.34 
3.2.3 Interaction between Pt-complexes and PEI-AuNPs 
 Having analyzed the nature of the interactions between the platinum complex 
(1) and PEI, PEI-coated AuNPs were incorporated to act as delivery vehicles to try to 
maximize the cancer cell killing ability of the prodrug. Taking advantage of the ability of 
this LMW PEI not only to form the outer-sphere complex with (1) but also to act as the 
reducing and stabilizing agent for the preparation of AuNPs, PEI-coated AuNPs were 
prepared for the delivery of (1). The use of this nanoparticle based system for the 
successful delivery of a chemotherapeutic agent, poly(I:C), has already been described 
in the previous chapter. Employing similar PEI-AuNPs for the delivery and activation of 
the Pt(IV) prodrug (1) will not only prove the versatility of these NPs as drug delivery 
systems, but also exploit a novel approach taking advantage of outer-sphere 
interactions between PEI and the platinum prodrug. 
The PEI-AuNPs were synthesized similarly to what has already been described in 
Chapter 2, following a single step reaction between the PEI and an aqueous solution of 
HAuCl4 at 90 ºC to form stable water soluble  PEI-coated AuNPs. The PEI-AuNPs used in 
this study presented a plasmon band at 521 nm (Figure 11). Transmission electron 
microscopy studies (TEM) confirmed the non-aggregated and spherical nature of the 
PEI-AuNPs having in this case a core size of 9.8 ± 1.8 nm (Figure 12).  
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Figure 11. UV-vis spectrum of the synthesized PEI-AuNPs showing the surface plasmon 
resonance band at 521 nm with a representative photograph of the PEI-AuNPs in 
water (inset). 
 
Figure 12. Representative low and high magnification TEM images and size distribution 
histogram of PEI-AuNPs showing an average diameter of 9.8 ± 1.8 nm. 
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The hydrodynamic diameter of the PEI-AuNPs in water was measured by dynamic light 
scattering (DLS). The nanoparticles had an average diameter of 19.9 ± 1.1 nm with 
relatively narrow size distribution (polydispersity index (PDI) = 0.331 ± 0.035) (Figure 
13). The zeta potential studies confirmed the presence of the positively charged PEI on 
the AuNPs (zeta potential = +34.15 ± 0.48 mV). After the addition of (1) to the 
positively charged nanoparticles (at 100 µM Au and 1 mM Pt), the surface charge of 
the PEI-AuNPs changed to less positive values (zeta potential= +13.70 ± 0.52 mV) 
confirming the interaction. 
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Figure 13. Hydrodynamic diameter of the synthesized PEI-AuNPs. 
3.2.4 Intracellular delivery studies 
3.2.4.1 Synthesis of FITC-labelled PEI-AuNPs 
 To investigate the cellular internalization behaviour of these PEI-AuNPs, the PEI 
was modified to incorporate fluorescein isothiocyanate (FITC) as described in previous 
literature.35 After the modification, the FITC-labelled PEI was used to synthesize the 
fluorescent PEI-AuNPs similarly to the non-labelled ones. To confirm the presence of 
the FITC in the purified PEI-AuNPs, the absorption and fluorescence emission spectra 
were recorded (Figure 14).  
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Figure 14. UV-vis absorption (continuous line) and fluorescence emission (dashed line) 
spectra of the FITC-labelled PEI-AuNPs. 
Despite the overlap between the AuNP plasmon band and the absorption spectrum of 
the fluorophore, the band corresponding to the FITC can be observed at 505 nm in the 
UV-vis spectrum of the FITC-labelled PEI-AuNPs. The fluorescence emission spectrum 
of the system also confirms the presence of FITC, hence the effective labelling of the 
system, showing the characteristic green fluorescence band of the fluorescein. 
3.2.5 Flow cytometry and fluorescence microscopy 
 The fluorescently labelled material was used to study the cellular uptake by PC-
3 human prostate cancer cells using both live cell fluorescence microscopy and 
fluorescence activated cell sorting (FACS) (Figure 15). The uptake of PEI-AuNPs with 
and without (1) can be clearly seen in the live cell fluorescence images, where after 45 
min incubation, the green fluorescence due to the FITC appears in the cytoplasmic 
region of the cells (nuclei stained in blue). FACS experiments also corroborate the rapid 
uptake of the AuNPs incubated at three different concentrations. 
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Figure 15. Fluorescence microscopy images taken of live PC-3 cells after 45 min 
incubation with FITC-PEI-AuNPs (A) and FITC-PEI-AuNPs/(1) complexes (green) (B). The 
nuclei are stained with Hoechst 33342 (blue). Flow cytometry histograms of PC-3 cells 
incubated with FITC-PEI-AuNPs for 45 min at different gold concentrations (green line) 
and non treated controls (solid grey peak). 
3.2.6 In vitro cell killing efficacy 
 In vitro studies were carried out to prove the feasibility of using both the non 
toxic LMW PEI polymer and PEI-coated AuNPs to achieve intracellular delivery and 
activation of (1). The ability of these novel outer-sphere coordination complexes to kill 
different human cancer cells was studied. Apart from the highly aggressive prostate 
cancer cell line PC-3, two other clinically relevant cells were selected to test the cancer 
cell killing efficacy of the system, a cisplatin resistant human breast cancer cell line 
(MDA-MB231) and the pancreatic cancer cell line PANC-1, a type of cancer known to 
have a particularly poor prognosis. 
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3.2.6.1 Cytotoxicity of PEI-Pt outer-sphere complexes 
First the cytotoxicity profile of the LMW PEI vehicle was determined in the 
three cell lines selected (PC-3, MDA-MB231 and PANC-1), and as it can be observed in 
the graph below (Figure 16) for each cell line there is a wide range of concentrations 
where the PEI vehicle causes no significant cytotoxicity. 
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Figure 16. Cytotoxicity profiles PEI PC-3, MDA-MB231 and PANC-1 cell lines. 
As well as the LMW PEI, the prodrug (1) also proved to be non toxic in all the cell lines 
over a broad range of concentrations (Figure 16). When combined however, the cell 
killing ability of the prodrug (1) was clearly enhanced in all three human cancer cell 
lines (Figure 17), indicating the validity of the outer-sphere approach to enhance the 
cancer cell killing ability of the platinum prodrug (1). 
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Figure 17. Cytotoxicity profiles of PEI-(1) mixtures (red) and (1) (black) in PC-3, MDA-
MB231 and PANC-1 cell lines ([PEI] = 1 µM). 
To elucidate the relative importance of each of the ligand types present in the 
inner-sphere of (1) towards promoting the outer-sphere interactions with the PEI 
polymer and the consequent cytotoxicity, two other Pt(IV) complexes, c,c,t-
[Pt(NH3)2(OCH2CO2)(O2CCH2CH2CO2)2]
2- (2) and c,c,t-[Pt(NH3)2Cl2(OH)2] (3) were also 
investigated (Figure 18). The nedaplatin derivative (2) will help determining the role of 
the cis-chloro ligands, while the neutral complex (3) will be used to assess the 
importance of the negatively charged axial succinate ligands. 
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Figure 18. Structures of the platinum complexes (1), (2) and (3). 
In contrast to the results with the prodrug (1), PEI had no effect on the cancer cell 
killing ability of the neutral complex (3) (Figure 19). In agreement with the NMR 
studies, this result suggests that the interactions arising from the anionic succinate 
ligands are crucial for stabilizing the PEI-(1) outer-sphere complexes. To elucidate the 
importance of the chloro ligands, complex (2) was tested in a similar manner. The 
addition of PEI only increased the cytotoxicity of (2) in MDA-MB231 cells and the effect 
was not as notable as for (1) (Figure 19). Thus, it becomes clear that interactions with 
the two cis-chloro ligands are also important in promoting the formation of the PEI-(1) 
outer-sphere complexes. 
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Figure 19. Cytotoxicity profiles of PEI-(3) mixtures (orange) and (3) (black) in PC-3, 
MDA-MB231 and PANC-1 cell lines (left column) and cytotoxicity profiles of PEI-(2) 
mixtures (blue) and (2) (black) in PC-3, MDA-MB231 and PANC-1 cell lines (right 
column) ([PEI] = 1 µM). 
3.2.6.2 Cytotoxicity of PEI-AuNP-Pt 
Having determined that both the chloro and the axial succinate ligands are 
crucial for the outer-sphere complex to promote cancer cell death, the prodrug (1) was 
selected to take the system a step further by incorporating the AuNP delivery system. 
The ability of the PEI-AuNPs to deliver and activate the Pt(IV) (1) was studied in the 
aforementioned cancer cell lines. As shown in Figure 20, the efficacy of the outer-
sphere complex in the presence of the AuNP is similar to that of the PEI-(1) 
combination in PC-3 cells but increased for both MDA-MB231 and PANC-1 cells lines. 
These results prove that the PEI-coated AuNPs can be successfully used to enhance the 
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cancer cell-killing ability of the Pt(IV) prodrug (1) through outer sphere coordination 
interactions with the PEI.  
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Figure 20. Cytotoxicity of PEI, PEI-AuNPs, PEI-(1) and PEI-AuNP-(1) outer-sphere 
complexes in PC-3, MDA-MB231 and PANC-1 cells after 72h. [(1)] = 100 µM, [PEI] = 1 
µM, [Au(0)] = 10 µM. 
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3.3 Conclusions 
In conclusion, this work demonstrates the applicability of outer-sphere 
coordination chemistry to promote intracellular delivery and activation of a Pt(IV) 
prodrug using a non toxic LMW PEI. The PEI-Pt(IV) prodrug outer sphere complex is 
promoted by interactions with each of the first coordination sphere ligands, and 
results in more facile reduction to Pt(II), succinate release and significantly enhanced 
cytotoxicity in several human cancer cell lines.  
The significance of these findings lies in the wide range of available PEI-derived 
compounds and PEI-modified drug delivery vehicles as well as Pt(IV) prodrugs which 
can be used for tuning and applying successfully this novel outer-sphere coordination 
chemistry approach for clinical applications. Delivering and activating the Pt(IV) 
prodrugs with PEI-coated AuNPs in particular, opens up fascinating opportunities to 
combine synergistically gene therapy with chemotherapy, and chemotherapy with 
radiotherapy or PTT. Moreover, similarly to in Chapter 2, the incorporation of the 
AuNP and the already proved suitability of gold based nanomaterials as X-ray and 
multimodal contrast agents provides  the potential for monitoring  the efficacy of 
tumour delivery and the therapeutic response using current clinical molecular imaging 
approaches. 
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3.4 Experimental Section 
3.4.1 Materials 
All syntheses were carried out with the following commercially available 
reagents used without further purification. Potassium tetrachloroplatinate(II) (99%) 
was purchased from Precious Metals Online. Polyethyleneimine (branched, 1.8 kDa, 
99%; 36% NH2, 29% NH and 35% N determined by NMR studies) was purchased from 
Alfa Aesar. Hydrogen tetrachloroaurate(III) trihydrate (99.99%), succinic anhydride 
(99%), potassium iodide (≥ 99.5%), potassium chloride (≥ 99.0%), silver nitrate (≥ 
99.0%), hydrogen peroxide solution 30% (w/w) in H2O, ammonium hydroxide solution 
(30-33% NH3 in H2O), glycolic acid (99%), L-ascorbic acid (> 99.5%), fluorescenin 
isothiocyanate (FITC, isomer I), sulforhodamine B sodium salt and trichloroacetic acid 
(> 99%) were purchased from Sigma Aldrich. 
3.4.2 Synthesis of Pt-complexes 
Cisplatin was synthesized as described previously.36 Briefly K2PtCl4 (1.5 g, 3.6 
mmol) was dissolved in water (15 mL) and KI (2.49 g, 15 mmol) was added and the 
mixture was stirred at room temperature for 10 minutes. A solution of NH4OH:H2O 
(1:1, 1.2 mL) was added and the mixture was stirred for further 30 minutes. The 
precipitate ([Pt(NH3)2I2]) was filtered, washed and dried (1.15 g, 2.38 mmol, 66.0%). To 
this complex, AgNO3 (0.79 g, 4.65 mmol) and water (36 mL) were added and the 
mixture was stirred at 70 ºC for 1 h 30 min. After that the mixture was filtered and the 
filtrate collected. KCl (0.39 g, 5.23 mmol) was added to the filtrate and stirred at 70 ºC 
for 1 h. The resulting yellow precipitate, cisplatin, was filtered, washed with cold water 
and dried (517 mg, 47.9%). 
c,c,t-[Pt(NH3)2Cl2(OH)2] (3)
  was prepared as previously described.23 Briefly a 
cisplatin suspension (0.18 g, 0.6 mmol) was prepared in water (1.5 mL) and H2O2 (9 mL, 
30%) added. The mixture was left stirring at 50 ºC for 3 h and then cooled down 
overnight. The product was filtered and washed with cold water and ethanol and dried 
(163 mg, 81.3%). 
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c,c,t-[Pt(NH3)2Cl2(O2CCH2CH2CO2H)2 (1) was prepared as previously described.
22 
Briefly c,c,t-[Pt(NH3)2Cl2(OH)2] (163 mg, 0.49 mmol) and succinic anhydride (195 mg, 
1.95 mmol) were dissolved in DMSO (1 mL) and stirred at 70 ºC for 24 h. After the 
addition of water (5 mL) the reaction mixture was lyophilized and the resulting solid 
washed several times with ice cold acetone (172 mg, 65.8%). 
c,c,t-[Pt(NH3)2(OCH2CO2)(O2CCH2CH2CO2H)2] (2) was prepared as previously 
described.24 Briefly to a suspension of c,c,t-[Pt(NH3)2(OCH2CO2)(OH)2] (previously 
synthesized)24 (0.2 g, 0.59 mmol) in DMF (10 mL) succinic anhydride (0.24 g, 2.4 mmol) 
was added and left stirring at 70 ºC for 24 h. The product was then lyophilized and 
washed several times with ice cold acetone (112 mg, 35.4%). 
3.4.3 Synthesis PEI-coated AuNPs 
PEI-coated AuNPs were prepared and characterized as described in the 
experimental section of Chapter 2. 
3.4.4 Synthesis FITC-labelled PEI and FITC-labelled PEI-AuNPs 
FITC-labelled PEI (FITC-PEI) was prepared as described elswhere.35 An aqueous 
solution of PEI 1.8 kDa (35 mg, 13.9 µmol, 500 µL) was added to FITC (5 mg, 12.8 µmol) 
dissolved in 5 mL H2O:DMSO (1:1). The mixture was stirred overnight in the darkness 
and later dialyzed against H2O for 2 days (MWCO 2000 kDa) to remove any unbound 
FITC until no fluorescence could be detected in the dialysate. The resulting FITC-
labelled PEI was then lyophilized. FITC-labelled PEI-AuNPs were prepared as described 
in the experimental section of Chapter 2 by using the FITC-labelled PEI instead of the 
normal PEI. 
3.4.5 Sample preparation 
All samples were freshly prepared simply by mixing an aqueous solution of the 
protonated Pt(IV) complexes at the appropriate concentrations with an aqueous 
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solution of PEI or PEI-coated AuNP (concentrations given in the figure captions). For 
the NMR studies the solvent was D2O and the pH was adjusted by adding small 
amounts of NaOH over the pH range 4-8. For the electrochemistry experiments 10 mM 
PBS pH 7.4 was used to prepare the solutions and ultrapure water was used in the case 
of samples for cell culture. For the cell culturing experiments, prior to the incubation 
with the cancer cells, the samples were left to interact for ca. 30 minutes and then 
were diluted 1/10 in cell culture medium and directly added to the cells to ensure no 
loss of reagents. The concentration of Pt(IV) complexes was determined by ICP-MS and 
the concentration of PEI was calculated taking the average MW of 1.8 kDa. In the 
studies with PEI-AuNPs, the gold concentration refers to Au(0) determined from the 
UV-Vis spectrum of the nanoparticle stock solution once purified to remove any excess 
of reagents. This Au(0) concentration can be directly correlated to the absorbance 
value at 400 nm.37 
3.4.6 Cell culture experiments 
 PC-3 human prostate cancer cell line was obtained from the American Type 
Tissue Collection (ATCC) and cultured in Ham’s F-12K (Kaighn’s) medium (Glibco) 
supplemented with 10% foetal bovine serum (Invitrogen) and 1% 
penicillin/streptomycin (Invitrogen) at 37 ºC under 5% CO2. Cells were passaged at 
~70% confluence and a low passage number was maintained using cryopreserved 
stocks stored in foetal bovine serum supplemented with 10% DMSO (Sigma Aldrich). 
MDA-MB231 human breast cancer cell line and PANC-1 human pancreatic carcinoma 
cell line were obtained from ATCC and European Collection of Cell Cultures (ECACC) 
respectively and were cultured in RMPI medium 1640 (Lonza) with 10% foetal bovine 
serum (Invitrogen), 1% L-glutamine and 1% penicilin/streptomycin (Invitrogen) at 37 ºC 
under 5% CO2. Cells  were passaged at ~70% confluence and a low passage number 
was maintained using cryopreserved stocks stored in foetal bovine serum 
supplemented with 10% DMSO. 
Cell viability studies. The cell viability was measured using the sulforhodamine B 
assay.38 For cell viability measurements, PC-3, MDA-MB231 and PANC-1 cells were 
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pated at 2000 cell/well density on 96-well plates and allowed to adhere overnight. All 
the formulations were diluted 1/10 in medium and incubated at 37 ºC using 200 µL of 
sample per well in quintuplets. After 72 h, the cells were fixed by the addition of ice 
cold 25% trichloroacetic acid (TCA) solution prior to staining with the SRB dye solution 
(0.4% w/v in 1% glacial acetic acid). The plates were washed with 1% glacial acetic acid, 
air-dried and resuspended in Tris buffer (10 mM, pH 10.5) before reading the 
absorbance at 550 nm. Curve fitting and interpolation of the IC50 values was carried 
out using GraphPad Prism 4 software. 
Cell imaging. PC-3 cells were seeded in an Ibidi 18 well µ-Slide at 4000 cell/well 
density and allowed to adhere overnight in an incubator (37 ºC, 5% CO2) in Ham’s F-
12K (Kaighn’s) medium. The medium was changed and the nuclei were stained with 
Hoechst 33342 (1 µg/mL) for 5 minutes, washed with sterile PBS 10 mM and incubated 
with the FITC containing nanoparticle formulations for 45 minutes. The medium was 
them removed, cells washed with sterile PBS 10 mM and fresh medium was added. 
The cells were visualized using a Zeiss Axio Observer wide field fluorescence images 
were collected and processed using Axio Vision software. 
Cellular uptake by flow cytometry. PC-3 cells were trypsinized and collected into 
cytometer tubes (1x105 cells/tube). The cells were centrifuged (1000 rpm, 5 min, 4 ºC) 
in order to discard the media and the pellet was resuspended in the formulations 
diluted in cell culture media (200 µL/tube). After 45 minutes of incubation at 37 ºC, the 
cells were centrifuged (1000 rpm, 5 min, 4 ºC) and washed once with cold PBS 10 mM. 
Finally the cell pellet was resuspended in 0.4 mL cold cytometer buffer (1% bovine 
serum albumin (BSA) and 0.1% sodium azide in PBS 10 mM). Cells were kept on ice 
until the analysis. The cellular uptake of the different formulations was measured using 
FACS Canto II (BD Bioscience) and the data was analyzed with FlowJo, LCC software. 
PC-3 cells were electronically gated based on forward area and height scatter 
parameters. The laser excitation wavelength used for FITC was 488 nm and the 
emission filter 530/30 nm. Each analysis represented the acquisition of 10000 cells per 
sample. 
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3.4.7 Instrumentation 
NMR studies. 1H NMR spectra were recorded on a Bruker Avance 500 NMR 
spectrometer at 298 K. Data processing was carried out using Mnova software.1H NMR 
spectra for (1), (2) and (3) were recorded in 10% D2O in H2O for characterization and in 
D2O with in combination with PEI and ascorbic acid; in all cases the chemical shifts 
were expressed relative to the water peak at 4.8 ppm. 
XPS measurements. XPS experiments were performed in a SPECS Sage HR 100 
spectrometer with a non-monochromatic X-ray source (Magnesium K line of 1253.6 
eV energy and 250 W), placed perpendicular to the analyzer axis and calibrated using 
the 3d5/2 line of Ag with a full width at half maximum (FWHM) of 1.1 eV. The selected 
resolution for the spectra was 15 eV of Pass Energy and 0.15 eV/step for the detailed 
spectra of the Pt 4f peaks. The deconvolution of the Pt 4f peaks was carried out at 36 s 
of X-ray exposure. The deconvolution allowed to estimate the ratio of the Pt(II) and 
Pt(IV) states. All measurements were made in an ultra high vacuum (UHV) chamber at 
a pressure below 5·10-8 mbar. In the fittings Gaussian-Lorentzian functions were used, 
where the FWHM of all the peaks were constrained while the peak positions and areas 
were set free. 
TEM. TEM studies were conducted in a JEOL JEM-2011 electron microscope operating 
at 200 kV. The samples were prepared by depositing a drop of nanoparticle solution 
onto a copper specimen grid coated with a holey carbon film and allowing it to dry. For 
nanoparticle size determination a minimum of 300 particles were measured using the 
Image J software. 
UV-Vis and Fluorescence spectroscopy. UV-vis measurements were performed 
in H2O using a Varian Cary 5000 spectrophotometer. Absorbance measurements on 
96-well plates were carried out on a TECAN Genios Pro 96/384 multifunction 
microplate reader. Fluorescence emission spectra were recorded with a Horiba Jovin 
Ibon Fluorolog fluorometer. 
DLS and ζ-potential. Particle size analysis was performed using a NanoSizer 
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(Malvern Nano-ZS, UK) with 173° scattering angle at 25 ºC. Each sample was measured 
at least in triplicate. Ζ-potential measurements were carried out with the same 
NanoSizer equipment at 25 ºC and a cell drive voltage of 20 V using a Smoluchowski 
model. 
Flow cytometry. All flow cytometry experiments were carried out in a FACS Canto II 
(BD Bioscience) system, which has an excitation source composed of three lasers: 
violet (405 nm), blue (488 nm) and red (633 nm). The laser excitation wavelength used 
for FITC was 488 nm and the emission filter 530/30 nm. In all measurements cells were 
electronically gated based on forward and side scatter parameters and the not-singlet 
events leaved out based on forward area and height parameters. Each analysis 
represented the acquisition of 10000 cells per sample and data was analyzed with 
FlowJo LLC software. 
Fluorescence microscopy. Live cell fluorescence images were obtained using Zeiss 
Axio Observer wide field fluorescence microscope (Carl Zeiss, Germany). A colibri LED 
module was used for fluorescence excitation: 365 nm excitation for Hoechst staining 
and 470 nm excitation for FITC.  Fluorescence emission was collected using a high-
efficiency multi-band pass colibri filter set which included a 402-488 nm bandpass for 
Hoechst and 500-557 nm for FITC. Brightfield and fluorescence images were collected 
and processed using AxioVision software. 
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4.1 Introduction 
Metastatic melanoma is one of the most aggressive and challenging types of 
cancer to treat, with a 5 year survival rate between 5-19%.1 Surgery, radiation and 
systemic treatments are used for treatment of curable melanoma and remain as the 
main treatment options in the management of patients with metastatic disease. 
However, one of the main causes behind the low survival rate is the notoriously 
resistant nature of melanoma to chemotherapy. Approved over 3 decades ago, 
dacarbazine continues to be the standard chemotherapeutic drug against melanoma.2 
Despite being the main treatment for a wide variety of cancers, the contribution of 
cisplatin towards melanoma has been somewhat limited. Platinum derivatives 
including cisplatin and carboplatin have a moderate antitumour effect, but similarly to 
the use of dacarbazine, they are limited by low response rates.2 Hence, the majority of 
the research has been oriented towards combined therapy using platinum derived 
drugs together with immunotherapy, gene therapy and different small molecules in 
search for a synergistic effect.3–6 Kubo et al. for example reported the combined use of 
cisplatin, interferon-β and IL-2 for tumour growth inhibition in a B16-F1 murine 
melanoma model.7 
The main limitation of traditional chemotherapeutics and combined approaches 
relates to their poor penetration into the tumour and lymph nodes involved in 
metastatic processes. With up to 80% of melanomas resulting in metastatic spread 
through the lymph nodes,8 the traditional intravenous administration of anticancer 
drugs is not able to provide sufficient lymphatic accumulation. Current clinical options 
towards treatment of lymph node metastases frequently involve complete lymph node 
dissection, a procedure associated with complications such as lymphatic oedema or 
infection and prolonged hospitalization.9 Therefore, the development of 
chemotherapeutic agents capable of efficiently accumulating in the tumour and lymph 
nodes could potentially lead to more successful treatment of the metastatic disease.  
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Figure 1. Lymphatic spread of the melanoma tumour cells from the primary location to 
the draining lymph nodes and the ultimate formation of distant organ metastases. 
Nanomedicine stands out as a particularly intriguing approach to assist in the 
lymphatic delivery and tumour accumulation of anticancer drugs. Due to their size and 
unique features, nanoparticles can not only be designed to target tumour tissue but 
also to selectively accumulate in lymph nodes and traffic through the lymphatic 
system.10,11 Subcutaneous administration of nanocarriers has already shown great 
potential for lymphatic delivery of anticancer drugs.12 Many different preparations 
have been explored for the treatment of melanoma, including liposomes, polymer 
nanoparticles and inorganic nanoparticles delivering various anticancer drugs.13,14 
Zhang et al. for example prepared paclitaxel loaded Pluronic (F123 and F127) 
polymeric micelles for the treatment of a pulmonary metastatic melanoma mouse 
model (B16-F10).15 With such preparation, the authors were able to prolong the blood 
circulation time and tumour accumulation of the drug as well as an improved 
therapeutic effect compared to Taxol. A similar strategy based on polymeric 
nanoparticles was reported by Talelli et al., who developed a covalent encapsulation of 
doxorubicin into cross-linked polymer micelles.16 A biodegradable block copolymer 
was used to form the micelles in which a methacrylamide derivative of doxorubicin 
was covalently incorporated through free radical polymerization. Designed to release 
the drug payload in acidic conditions, this construct demonstrated its enhanced 
therapeutic efficacy compared to free doxorubicin in the same murine melanoma 
model (B16-F10). 
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Nanocarriers for the delivery of platinum based drugs against melanoma have also 
been reported over the last few years. For example, Yang et al. developed a 
hyaluronan-conjugated cisplatin system which shows improved antitumour efficacy in 
a murine melanoma model compared to standard cisplatin treatment.17 Tao and co-
workers on the other hand described the covalent attachment of cisplatin to poly-N-
isopropylacrylamide (PNIPAM) and polyethyleneglycol (PEG) coated AuNPs.18 This pH-
sensitive construct showed enhanced cytotoxicity in A875 melanoma cells due to the 
liberation of the drug under the acidic conditions of the intracellular environment. In a 
more recent example Cabral et al. developed a platinum (II) drug loaded polymeric 
micelle construct that were able to target and fight lymph node metastases following 
systemic administration.19 The authors explored the therapeutic efficacy of the system 
in a highly aggressive metastatic melanoma mouse model (B16-F10) and highlighted 
the importance of the size of the nanocarrier, which played a key role in achieving an 
improved therapeutic efficacy compared to the free drug and even the clinically used 
doxorubicin-loaded liposome preparation (Doxil).19 
 
Figure 2. Schematic representation of three nanoparticle based delivery vehicles for 
the treatment of melanoma. (A) Paclitaxel loaded polymeric micelle,15 (B) cross-linked 
block-copolymer micelles with covalently entrapped doxorubicin16 and (C) PNIPAM and 
PEG coated AuNPs for the delivery of cisplatin.18 
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Beyond their role as drug delivery vehicles, nanoparticles can also be conceived 
to function as contrast agents for diverse imaging modalities for early detection of 
tumours and metastases, as well as real time tracking of the drug and its therapeutic 
efficacy. Particularly interesting is the possibility of not only selectively delivering 
anticancer agents to the tumour and lymphatic system but also being able to non-
invasively visualize these areas of interest. Indeed, the early detection of metastases in 
the lymph nodes is a key aspect for improving the therapeutic outcome of melanoma. 
In this regard, recent efforts have been focussed on the design of nanoparticles that 
able to accumulate and traffic through the lymphatic system also incorporate 
capabilities for high resolution and sensitive imaging. 
Lim et al. reported a thermally cross-linked superparamagnetic IONP system for MRI 
contrast enhancement and its applicability for the detection of metastatic lymph nodes 
in a melanoma mouse model (B16-F1).20 Mareque-Rivas and co-workers described the 
use of IONP-filled PEG-phospholipid micelles for lymphatic delivery of 
immunostimulatory drugs and multimodal MRI/SPECT imaging. This system initially 
took advantage of the intrinsic nature of the IONPs as MRI contrast agents and 
incorporated 99mTc as a radioisotope for SPECT imaging.21  67Ga radiolabelling of a 
similar IONP-based system was reported for image tracked lymphatic delivery of an 
antigen/adjuvant combination against melanoma.22 
Based on the successful lymphatic delivery of IONP-based micelles, their 
excellent imaging capabilities as well as the potential of platinum based drugs and 
prodrugs against melanoma, this work focused on investigating the properties of IONP-
filled PEG-phospholipid micelle nanocarriers to deliver of a cisplatin platinum (IV) 
prodrug for the treatment of melanoma. 
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4.2 Results and Discussion 
4.2.1 Synthesis and characterization of PEG-Pt 
Adopting the Pt(IV) prodrug approach, the inert Pt(IV) prodrug cis,cis,trans-
[Pt(NH3)2Cl2(O2CCH2CH2CO2H)2] (1) was selected for attachment and delivery using 
water soluble IONPs micelles using a protocol previously described by the group.23 This 
prodrug is capable of releasing cytotoxic Pt(II) species upon intracellular reduction 
inside tumour cells.24 Its use in combination with a nanoparticle based delivery system 
was expected to facilitate prodrug delivery to the area of interest (i.e. tumour and 
tumour draining lymph nodes). The use of dicyclohexylcarbodiimide (DCC) coupling 
chemistry allows the conjugation of the prodrug to the amine end group of a 
commercially available PEGylated phospholipid (PEG-NH2). Following the reaction, any 
unbound (1) is removed via dialysis and the purified phospholipid (PEG-Pt) (Figure 3) 
recovered by freeze-drying. Adding an excess of (1) in the reaction ensures that only 
one of the axial ligands on the Pt(IV) complex reacts with the phospholipid molecule, 
minimizing unwanted side products. 
 
Figure 3. Structure of the Pt-modified PEGylated phospholipid (PEG-Pt). The amide 
bond is highlighted in red. 
The characterization of the final product by UPLC-MS (Figure 4) reflects a change in the 
retention time compared to the initial PEG-NH2, indicating a change in polarity, hence 
in the structure. The lower retention time of the Pt(IV)-modified phospholipid indeed 
suggests a more polar nature of the compound, resulting in less affinity for the 
stationary phase (reverse phase column, apolar).  
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Figure 4. Typical chromatograms obtained for the PEG-Pt final product and the initial 
PEG-NH2 as a control (top). Positive ESI-MS m/z spectra of the parent PEG-NH2 
(control) and the PEG-Pt product (bottom): m/z for [PEG-NH2+H
++NH4
+]2+ 
(C132H267N3O54P) expected = 1395.74, found = 1396.30; m/z for [PEG-Pt+2H
++3NH4
+]3+ 
(C140H289N7O61PPtCl2) expected = 1114.89, found = 1113.86. 
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The ESI-MS spectrum in Figure 4 indicates a successful incorporation of the prodrug, 
showing an isotopic pattern in accordance with PEG-containing polymers and an 
experimental m/z value (1113.86) very close to the expected one (1113.33). The 1H 
NMR spectrum also agrees with the formation of PEG-Pt as new peaks due to the 
Pt(IV) prodrug’s succinate ligands are present at ca. 2.5 ppm (Figure 5).  
 
Figure 5. 1H-NMR spectra of PEG-Pt and unmodified PEG-NH2 in D2O (water 
suppression).  
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Figure 6. XPS spectrum of PEG-Pt showing the expected binding energy of the Pt 4f 
regions for Pt(II) (green) and Pt(IV) species (blue). 
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XPS analysis of the Pt 4f region also confirms that the oxidation state of the platinum 
centre remains as Pt(IV) even following the conjugation (Figure 6). In accordance with 
the literature data for Pt(IV) species, the characteristic Pt(4f7/2) and Pt(4f5/2) appear at 
75.5 eV and 78.8 eV respectively while any peaks corresponding the Pt(II) oxidation 
state (at 72.7 eV and 76.1 eV) are absent. 
4.2.2 Synthesis and characterization of IONPs and water soluble IONP 
micelles 
Hydrophobic IONPs were prepared by thermal decomposition of an iron (III) 
precursor using oleylamine and oleic acid as surfactants and 1,2-hexadecanediol as the 
reducing agent. Adjusting the experimental conditions, the shape and morphology of 
the resulting particles was controlled to obtain spherical 6-7 nm IONPs.25 The TEM 
characterization of the synthesized nanoparticles (Figure 7) shows monodisperse and 
spherical IONPs with a mean core diameter of 6.6 ± 0.9 nm.  
 
Figure 7. Representative TEM image of the hydrophobic IONPs used for the micelle 
preparation. 
IONPs prepared by thermal decomposition methods result in hydrophobic 
materials that need further modification to achieve the water solubility required for 
biomedical applications. Among the many different polymers and ligands that impart 
water solubility and biocompatibility to hydrophobic IONPs, polyethyeneglygol (PEG) 
and its derivatives represent a very interesting alternative and have indeed been 
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widely used.26 PEG polymers have low toxicity and immunogenicity and several 
PEGylated products have been approved by the FDA (Food and Drug Administration) 
for clinical use.27 PEGylated phospholipids in particular offer a great scaffold for further 
chemical modification through their terminal functional groups, allowing the 
incorporation of different moieties such as the prodrug described above. The use of 
this kind of commercially available PEGylated phospholipids to form micelles 
encapsulating nanoparticles and other kinds of hydrophobic molecules has been 
reported in different biomedical applications.28  
In this work the intercalation of the amphiphilic PEGylated phospholipids between the 
oleic acid chains on the surface of the nanoparticles leads to the formation of stable 
and water soluble micelles based on a modification of the lipid hydration method 
previously used by the group.29 Any free phospholipid can then be eliminated by 
ultracentrifugation, leading to purified micelles that are stable in either water or saline 
solution. The covalent attachment of the platinum (IV) prodrug to the PEGylated 
phospholipid allows the formation of prodrug-loaded water soluble IONP micelles 
following the same lipid hydration strategy. In order to compare the Pt(IV) prodrug-
loaded system against a prodrug-free control, the commercially available methoxy 
terminated phospholipid (PEG-OMe) was used to prepare unloaded micelles in a 
similar manner. 
The characterization and comparison between the loaded and unloaded 
micelles (Figure 8) shows the presence of small aggregates in both cases, with a slightly 
higher hydrodynamic diameter for the Pt-loaded micelles. The fact that the system is 
constituted of small aggregates not larger than 100 nm is highly desirable in this case. 
Indeed, it has already been described that this is the ideal size range for a 
subcutaneously injected nanocarriers to be able to enter the lymphatic system.30 Too 
large nanoparticles are mainly stuck in the injection site, while too small system will 
mostly be absorbed by the capillary network and go into systemic circulation. 
Nanocarriers between 10 and 100 nm on the other hand, maybe able to enter and 
traffic through the lymphatic system reaching the tumour site and draining lymph 
nodes, being able to potentially fight metastasis.  
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Figure 8. Representative TEM images and DLS size distribution of control (A) and Pt-
loaded (B) micelles. 
The change in zeta potential from -15.1 ± 2.1 mV to -26.9 ± 1.9 mV also reflects the 
attachment of the prodrug, where the carboxylate group of (1) provides a negative 
charge. In order to determine the loading capacity of the system, ICP-AES and ICP-MS 
analysis were performed to measure the iron and platinum content, resulting in an 
average of 150 molecules of (1) per IONP.  Using a representative example with an iron 
oxide core of 6.6 nm in diameter and a [Fe]/[Pt] ratio of 40 (in mM), the following 
calculations can be performed to determine the approximate number of prodrug 
molecules per nanoparticle.  
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Assuming a completely spherical nanoparticle and the known density of magnetite 
structure, the mass per nanoparticle can be determined: 
 VIONP = 4/3 · (D/2)
3 · π = 1.505 · 10-25 m3 
 ρ(Fe3O4) = 5.17 · 10
6 g·m3 
 m = ρ(Fe3O4) · VIONP = 7.783 · 10
-19 g 
Taking the molecular weight and the general formula of the iron oxide, the moles and 
atoms of iron can be determined. Together with the ICP results this data can be used 
to obtain an estimated nanoparticle concentration ([IONP]) and hence the 
approximate number of platinum molecules per IONP: 
 nFe = m · MW (Fe3O4) · 3 = 1.009 · 10
-20 mol 
 Featoms = nFe · NA = 6076 atoms 
 [IONP] = [Fe] / Featoms = 1.79 µM 
 [Pt] / [IONP] = 179 Pt molecules / IONP 
Fluorescently labelled micelles were also prepared in a similar way but with the 
addition of a commercially available rhodamine labelled phospholipid to the 
preparation. Figure 9 shows how the the incorporation of the rhodamine phospholipid 
does not affect the size or the ζ-potential of the micelles. From the UV-Vis and 
fluorescence spectra the absorption (λ = 570 nm) and emission (λ = 589 nm) peaks 
corresponding to the rhodamine can be easily identified (Figure 10). 
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Figure 9. Representation of the size distribution and ζ-potential of normal platinum 
loaded IONP micelles (black) and rhodamine-labelled IONP-Pt micelles (red). 
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Figure 10. UV-Vis absorption (continuous line) and fluorescence spectra (dashed line) 
of the unlabelled micelles (black) and the rhodamine-labelled IONP micelles (red). 
4.2.3 In vitro cell killing ability 
To study the cancer cell killing ability of the system in vitro, a sub-line of a 
highly aggressive and notoriously difficult to treat metastatic melanoma cell line (B16-
F10) was selected. The specific sub-line used in this case (B16-F10-OVA) has been 
engineered to express the full-length ovalbumin model antigen and although the 
expression of ovalbumin is not relevant for these studies it serves a purpose for the 
future combination of chemo and immunotherapy. In addition, this type of murine 
tumour cell line is widely used in research as a model for skin cancers and is indeed 
one of the most effective in terms of metastasis related research.31,32 
4.2.3.1 Cellular uptake studies 
The internalization of the Pt-loaded micelles was studied in B16-F10-OVA cells 
by both flow cytometry and live cell fluorescence microscopy (Figure 11). The 
incubation of the rhodamine labelled IONP-Pt micelles with B16-F10-OVA cells for 2 h 
and the later analysis by flow cytometry showed an efficient uptake of the NPs by the 
tumour cells. To gain further information on their intracellular localization, live cell 
  Chapter 4 
 
149 
fluorescence images were also acquired at the same time-point, confirming the uptake 
of the micelles which localize in the cytoplasm. 
 
Figure 11. (A) Flow cytometry histograms of B16-F10-OVA cells after 2 h incubation 
with rhodamine-labelled Pt-loaded IONPs (red line) and non treated cells (solid grey 
peak). (B) Overlay of brigthfield and fluorescence microscopy images of live B16-F10-
OVA cells after 2 h incubation with the aforementioned formulation (red). Nuclei are 
stained with Hoechst 33342 (blue). 
4.2.3.2 In vitro cytotoxicity studies 
To be able to compare between slightly different preparations for all the 
experiments regarding IONP micelles the concentrations refer to the iron or platinum 
contents determined by ICP. First the potential toxicity of the vehicle itself was 
assessed testing a range of different concentrations of unloaded IONP micelles. Figure 
12 shows that the IONP micelles do not produce any significant decrease in cell 
viability in a wide range of iron concentration even after 72 h of incubation.   
Accordingly, to evaluate the effect of the Pt(IV) prodrug the platinum loaded micelles 
were tested keeping the iron concentration at a non-toxic level. As the Pt/Fe ratio 
slightly varies between preparations, these studies refer to platinum concentration 
rather than iron.  
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Figure 12. Cytotoxicity profile of the unloaded IONP control micelles in B16-F10-OVA 
cells (72 h incubation). 
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Figure 13. Cytotoxicity profiles of cisplatin, (1), Pt-loaded IONP micelles and a mixture 
of unloaded IONP micelles and (1) in B16-F10-OVA cells after 72 h incubation. 
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The platinum loaded micelles were compared with the Pt(IV) prodrug alone and 
cisplatin at similar Pt concentrations. Figure 13 shows the cell viability curves for each 
of these three systems after 72 h incubation with B16-F10-OVA cells, where a clear 
increase on the cancer cell killing ability of (1) can be observed when is delivered by 
the IONP-filled PEG-phospholipid micelles compared to the prodrug alone. 
Remarkably, using this delivery vehicle the prodrug (1) is able to achieve an in vitro 
cytotoxic effect comparable to cisplatin. Importantly, the simple mixture of unloaded 
IONP micelles and (1) does not render any significant cytotoxic effect, corroborating 
that the covalent attachment of the prodrug is essential for a successful delivery and 
cytotoxic effect. 
4.2.4 Nuclear imaging: SPECT 
In addition to studying the in vitro internalization and cancer cell killing ability 
of the system, the assessment of its in vivo trafficking is also very important for the 
development of new drug delivery systems. For this purpose, nuclear imaging 
techniques such as PET and SPECT represent a non-invasive, rapid and effective tool to 
study the biodistribution and pharmacokinetics. Compared to imaging techniques like 
MRI or CT, one of the major advantages of using nuclear imaging relies on their high 
sensitivity, allowing the detection of extremely low amounts of radiotracers. 
4.2.4.1 Radiolabelling of the  IONP-Pt with 67Gallium 
Following a previously reported protocol that exploits the similarity between 
Ga3+ and Fe3+ ions,22 the gamma emitting radionuclide 67Ga was used to radiolabel the 
IONP micelles for SPECT imaging. This approach allowed the direct binding of Ga3+ ions 
without the need of additional steps to incorporate traditional organic metal chelator 
groups. Commercially available 67Ga citrate was first converted into 67Ga chloride and 
then incubated with the IONP micelles to achieve the radiolabelling.  
As shown in Figure 14 this protocol yielded very efficient radiolabelling of the 
platinum-loaded micelles with results comparable to those previously described.22 
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More importantly however, the radiolabelled system showed an excellent 
radiochemical integrity. Even in the presence of a large excess the current “gold 
standard” Ga3+ chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid) (ca. 106 mol DOTA per mol IONP), over 80% of the initial activity is retained. 
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Figure 14. (A) 67Ga radiolabelling efficiency of platinum-loaded IONP micelles and (B) 
stability profile of the radiolabelling in presence of large excess of competitor chelating 
ligand DOTA (ca. 106 mol DOTA per mol IONP). 
4.2.4.2 Biodistribution and in vivo trafficking 
As mentioned previously, tumour metastases not only spread through the 
circulation but also through the lymphatic system, where the draining lymph nodes are 
the most common sites of metastasis.33 For this reason the 67Ga-labelled IONP-Pt 
micelles were used to monitor the in vivo trafficking of the system in tumour bearing 
mice. Similarly to the in vitro studies, the highly aggressive B16-F10-OVA murine 
melanoma tumour model was used and the radiolabelled system was tracked using 
SPECT/CT at 3, 24 and 48h after the subcutaneous injection in the peritumoural region. 
Despite the intense signal still present at the site of injection, clear accumulation in the 
tumour and right inguinal lymph nodes can be observed 3 h after the subcutaneous 
injection of the IONP-Pt(IV) micelles (Figure 15). Notably, the presence of a strong 
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signal in the right axillary lymph node proves a successful lymphatic trafficking of the 
nanoparticles to distant sites. A similar biodistribution pattern is observed 24 h post-
injection, with a clear signal appearing in both the tumour and the aforementioned 
lymph nodes. After 48 h on the other hand, most of the remaining activity is in the 
tumour. Ex vivo SPETC images of the different organs confirm the in vivo observations 
(Figure 16). 
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Figure 15. SPECT/CT images 3, 24 and 48 h post injection. Detail of the signal intensity 
in the tumour area and the inguinal and axillary lymph nodes. 
 
Figure 16. Ex vivo images at 3, 24 and 48h showing the photograph of the selected 
organs and the corresponding SPECT images bLN: brachial LN; aLN: axillary LN; Lu: 
lungs; L: liver; S: spleen; T: tumour; K: kidneys; inLN: inguinal LN; iLN: iliac LN; (R): right 
side; (L): left side.  
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Gamma-counter analysis of the activity of the organs of interest is also in accordance 
with the SPECT images. As shown in Figure 17 the radiolabelled system preferentially 
accumulates in the tumour rather than other organs such as spleen, kidneys or liver. 
With regards to the lymph nodes, gamma counter results of the activity per lymph 
node clearly indicate a rapid accumulation in the right side lymph nodes, mainly the 
inguinal close to the site of injection but also the distant axillary lymph node and a 
slight signal in the inguinal as well.  
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Figure 17. (top) Ex vivo gamma-counter analysis of the selected organs at 3, 24 and 48 
h. Biodistribution expressed as percentage of injected dose per gram of tissue. 
(bottom) Ex vivo gamma-counter analysis of the selected lymph nodes at 3, 24 and 48 
h. Biodistribution expressed as percentage of injected dose per gram lymph node. (R): 
Right side, (L): left side. 
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These results corroborate the ability of the nanocarrier to accumulate in the tumour 
area. Moreover, it is also able to enter and traffic through the lymphatic system where 
not only they reach the inguinal lymph nodes proximal to the site of injection but also 
have the capacity to migrate to the distant axillary lymph nodes directly connected via 
lymphatic vessels.34  
4.2.5 In vivo therapeutic efficacy 
Encouraged by the enhanced in vitro cancer cell killing ability of the system as 
well as the efficient cellular uptake and accumulation in the tumour and tumour 
draining lymph nodes, the in vivo therapeutic efficacy of the IONP-Pt was assessed 
next.  
As an initial approach to determine if the presence of the IONP-Pt system would 
impact the development of the tumour, the treatment and the B16-F10 OVA cells were 
subcutaneously co-injected into the right back side of the mice. The administered 
platinum content was fixed to 0.55 mg per kilogram of animal weight as a single 
therapeutic dose. Throughout the experiment body weight and tumour size were 
monitored as indicators of the toxicity and efficacy of the therapy. In all cases the iron 
content was kept within the authorized doses for similar NPs (e.g. ferumoxytol).  
As shown in Figure 18 both cisplatin and IONP-Pt(IV) significantly inhibited tumour 
growth compared to the administration of the prodrug. Remarkably, the platinum-
loaded nanoparticle proved to be even more effective than cisplatin. While none of the 
formulations had an effect on the body weight, the tumour growth inhibition led to a 
significantly enhanced survival rate of mice treated with IONP-Pt(IV) (Figure 19), with 
all mice living over 10 more days than the control group and the  group treated with 
the prodrug alone. 
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Figure 18. (top) Effect of cisplatin, Pt(IV) prodrug and Pt-loaded IONPs (all at 0.55 mg 
Pt/kg) on the growth of tumours after subcutaneous co-injection with B16-F10 OVA 
cells in C57BL/6 mice. Mean values and standard errors of the mean are represented 
(n = 5 for each group). (bottom) Animal weigh of C57BL/6 mice co-injected 
aforementioned formulations and B16-F10 OVA cells. Mean values and standard errors 
of the mean are represented (n = 5 for each group). 
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Figure 19. Survival curves of C57BL/6 mice co-injected with cisplatin, Pt(IV) prodrug or 
Pt-loaded IONPs (all at 0.55 mg Pt/kg) and B16-F10 OVA cells. 
Following the promising results obtained with the co-injection the efficacy of 
the platinum-loaded nanocarrier was assessed in tumour bearing mice. To develop the 
tumour, the B16-F10-OVA cells were injected into the right back side of the mice and 
left to grow for 7 days before starting the treatment. Based on the literature about 
similar therapeutic efficacy studies,35 the administration of a total of 3 doses (one 
every three days) was selected as the treatment strategy. Similarly to the previous 
experiment, regarding body weight and tumour size were monitored throughout the 
treatment as indicators of the toxicity and efficacy of the therapy. The platinum loaded 
IONP micelles and the corresponding Pt(IV) and cisplatin controls were then 
subcutaneously injected in the peritumoural region fixing the Pt dose to 0.24 mg per 
kilogram of animal weight in all cases.  
In addition, a commercially available TGF-β inhibitor, LY364947 was incorporated to 
the treatment as a way to maximize the efficacy (Figure 20). When administered at a 
low dose, this small molecule has been described to inhibit the TGF-β type I receptor 
(TβR-I) and hence alter the tumour microenvironment to enhance the EPR effect, 
increasing the chances of the system to penetrate in the tumour area.36,37  
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Figure 20. Chemical structure of the commercially available TGF-β inhibitor LY364947. 
As it can be observed from the tumour volume progression in Figure 21 the IONP-Pt 
micelles slightly delayed the tumour growth compared to the prodrug alone and even 
cisplatin. When administered in combination with the TGF-β inhibitor however 
(referred to as INH in the figure), the development of the tumour was suppressed up 
to 10 days after the final dose. Moreover, the fact that no significant weight loss was 
detected suggests a good tolerance of the treatment. Most importantly the IONP-Pt 
system was more efficient with regards to survival than the prodrug and cisplatin, 
resulting in mice living up to 35 days, a very encouraging outcome for further 
development of the system towards the treatment of melanoma. 
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Figure 21. Effect of cisplatin, Pt(IV) prodrug and Pt-loaded IONPs (with and without 
TGF-β inhibitor) (all at 0.24 mg Pt/kg per dose) on the growth of tumours inoculated in 
C57BL/6 mice. Three doses of each formulation were administered every three days 
(marked with arrows) by subcutaneous peritumoural injection. Mean values and 
standard errors of the mean are represented (n = 5 for each group). Animal weight for 
tumour bearing mice treated with the aforementioned formulations. 
These results are very promising from the therapeutic point of view as the prodrug 
delivered with the IONP micelles is not only better than the prodrug alone, but also 
more effective than cisplatin. Compared to several other recent nanocarriers 
developed for platinum based anticancer therapy vivo, not only is this construct is less 
complex, but also it is able to achieve major tumour growth inhibition with lower 
doses of Pt. Similar in vivo antitumour studies report platinum doses ranging from 0.65 
to 1.2 mg Pt/kg for intratumoural administration38,39 and up to 4-5 mg Pt/kg for 
intravenous or intraperitoneal injections.40–46  
In addition, taking into account the highly aggressive nature of the tumour model 
selected for these studies, the administered dosage scheme (a dose every three days 
and a total of three doses) is able to achieve a remarkable tumour growth suppression 
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for over two weeks following the last administration. In a very similar experimental 
setup by Farokhzad et al. 5-fold larger platinum doses are administered close to the 
tumour area in a prostate cancer xenograft model twice a week for over 5 weeks.38 
Despite the sustained administration and in contrast to the results with the IONP-Pt 
system, the treatments failed to delay the tumour growth but only produced a slower 
but steady growth of the tumour (Figure 22). 
 
Figure 22. Tumour growth progression of LNCaP prostate cancer xenograft model 
treated with a platinum prodrug containing nanoparticles. Adapted from 38 
The improvement of the therapeutic efficiency of the system in the presence of 
the TGF-β inhibitor is quite remarkable, however it might not only be related to an 
increased uptake provoked the change in the permeability of the tumour 
microenvironment. TGF-β also plays an important role within the immune system, 
being indeed one of the immunosuppressive factors known to be secreted by tumour 
cells and that might among other aspects be involved in the ability of melanomas to 
evade immunotherapeutic approaches.47 Described in several studies, this cytokine has 
been described to cause a reduction in the activity of T lymphocytes and natural killer 
cells while producing an increase of regulatory T lymphocytes, therefore producing a 
deleterious effect over the immune response.48-50 Therefore, the administration of a 
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TGF-β inhibitor would help counteract the immunosuppressive effect of the cytokine 
and enhance the immune responses.51-52 
Although the platinum-loaded IONP micelles are designed for improving the 
chemotherapy, it is important to note that the hydrophobic nature of the IONP cores 
may also add an immunotherapeutic contribution to the system. Once injected in vivo 
the micelle structures are subjected to degradation over time, leading to the release of 
the hydrophobic IONP cores. Hydrophobic moieties or motifs have indeed been 
proposed to belong to an ancient family of DAMPs. Described by Seong and 
Matzinger,53 these hydrophobic portions which are often protected, act as universal 
DAMPs when they become exposed and are able to activate the innate immune 
system through interaction with TLRs. In this case, the micelle structure provides a 
stealth immunostimulatory component that only becomes active once the system has 
degraded in vivo. 
Therefore, the notably improved antitumour therapeutic efficacy of the IONP-Pt 
system showed in Figure 21 is most likely a combination of different contributions 
including the chemotherapeutic effect of the platinum prodrug, the 
immunostimulatory activity of the hydrophobic IONP cores and the effect of the TGF-β 
inhibitor in enhancing this immune response. 
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4.3 Conclusions 
This chapter has focused on the use of a covalent strategy to attach a platinum 
(IV) prodrug to PEG-phospholipids which then were used to prepare water soluble 
IONP-filled micelles, and testing the efficacy of these construct in an aggressive murine 
melanoma model. This simple construct fulfils many of the requirements for a 
successful drug delivery system for the treatment of metastatic melanoma. In vitro 
results indicate a rapid internalization of the system by cancer cells as well as an 
enhanced cytotoxicity of the prodrug when delivered with the micelle nanocarrier. 
Moreover, the size of the small micelle aggregates falls within the optimum range for 
lymphatic trafficking, a key aspect for the potential application against lymph node 
mediated metastatic spread. 
The use of a chelator-free strategy to incorporate 67Ga as a radiolabel allowed the use 
of highly sensitive nuclear imaging to track the biodistribution of the nanocarrier in 
vivo. SPECT images following the subcutaneous administration of the system indeed 
show the accumulation of the prodrug-loaded IONP micelles in the tumour as well as 
the effective uptake by the lymphatic system with migration to draining and distant 
lymph nodes. The in vivo therapeutic efficacy experiments have also led to promising 
results and made clear that the system has the potential to produce a strong 
therapeutic effect against metastatic melanoma.  
Moreover, in view of the results, the promising antitumour effect of the system might 
be due to a combination of different contributions. In addition to the 
chemotherapeutic effect given by the platinum prodrug, the intrinsically hydrophobic 
nature also provides the construct with a stealth immunostimulatory component. 
Finally, the use of a TGF-β inhibitor might not only serve as a way to enhance the 
penetration of the micelles into the tumour, but also reinforce the antitumour immune 
responses. 
In conclusion, this system can serve as the starting point for developing novel chemo-
immunotherapeutic constructs for melanoma that integrates different treatment 
modalities and imaging capabilities in a simple construct.  
  
  Chapter 4 
 
165 
4.4 Experimental Section 
4.4.1 Materials 
All syntheses were carried out with the following commercially available 
reagents used without further purification. Chloroform (water 0.005%) was purchased 
from LABSCAN, dimethylsulfoxide (≥ 99.5%) was purchased from Panreac. 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] (ammonium salt) (PEG-OMe), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (ammonium salt) (PEG-
NH2) and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissaminerhodamine B 
sulfonyl) (Rho-PS) were purchased from Avanti Polar Lipids. 4-(dimethylamino)pyridine 
(99%), N,N’-dicyclohexylcarbodiimide (99%), LY364947, sulforhodamine B sodium salt 
and trichloroacetic acid (> 99%) were purchased from Sigma.  
Cisplatin and cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2CO2H)2] (1) were prepared as described 
in chapter 3. Hydrophobic IONPs were prepared by Dr. N. Gómez Blanco following a 
previously described protocol.25  
4.4.2 Synthesis of PEG-Pt 
In a typical reaction, cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2CO2H)2] (1) (9.6 mg, 
18.0 µmol), dicyclohexylcarbodiimide (DCC) (3.7 mg, 18.0 µmol)  and 4-
(dimethylamino) pyridine (1.0 mg, 7.2 µmol) were dissolved in DMSO (130 µL). This 
solution containing the activated platinum (IV) complex was added to a DMSO solution 
of PEG-NH2 (10 mg, 3.6 µmol, 170 µL). The resulting mixture was allowed to react at 
room temperature for 72 h under continuous stirring and protected from the light. 
Water was then added to the reaction mixture and the solution was centrifuged to 
remove the insoluble material. The supernatant was filtered (0.45 µm) and dialyzed in 
a Slide-A-Lyzer dialysis cassette (Thermo Scientific, MW cut-off 2000 Da) against water. 
Finally the dialyzed product (PEG-Pt) was lyophilized and stored in a stock solution of 
10 mg/mL in 2:1 CHCl3:MeOH. 
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4.4.3 Synthesis of water soluble IONP micelles 
For the control micelles, hydrophobic Fe3O4 nanoparticles (0.5 mg) and PEG-
OMe (1 mg) were dissolved in chloroform (500 µL). The solvent was allowed to 
evaporate overnight at room temperature. Any remaining solvent was removed under 
vacuum. The dried residue was heated in a water bath at 80 ºC for 30 s and rehydrated 
in 1 mL of nanopure water. The solution was centrifuged at 7300 × g for 5 minutes. The 
pellet was discarded and the supernatant was filtered (0.45 µm). To eliminate the free 
PEG, the solution was ultracentrifuged (369000 x g, 45 min, three cycles). The final 
pellet was resuspended in a known volume of nanopure water or saline 0.9% solution. 
The purified micelles were stored at room temperature.  
For the platinum-loaded micelles, all the synthesis and purification steps were 
performed in darkness. Hydrophobic Fe3O4 nanoparticles (0.5 mg) and PEG-Pt (100 µL 
of a 10 mg/mL solution on 1:2 MeOH:CHCl3) were dissolved in chloroform (to a final 
volume of 500 µL). The solvent was allowed to evaporate overnight at room 
temperature. Any remaining solvent was removed under vacuum. The dried residue 
was heated in a water bath at 80 ºC for 30 s, after which 1 mL of nanopure water was 
added. The solution was transferred to a microtube and centrifuged at 1800 x g for 3 
minutes. The pellet was discarded and the supernatant was filtered (0.45 µm). To 
eliminate the free PEG, the solution was ultracentrifuged (140000 x g, 30 min, three 
cycles). The final pellet was resuspended in a known volume of nanopure water or 
saline 0.9% solution and stored at room temperature.  
Fluorescent micelles were prepared as above by introducing a commercial rhodamine 
labelled phospholipid into the mixture prior to the solvent evaporation (15 µL from a 2 
mg/mL solution). 
For ICP analysis, acid digestion of sample aliquots was carried out in concentrated 
HNO3. Prior to the measurements digested samples were diluted in nanopure water to 
a final acid concentration of 1-2%. 
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4.4.4 Cell culture experiments 
The B16-F10-OVA melanoma cell line was a gift from Dr. P. Sarobe (Centre for 
Applied Medical Research (CIMA), University of Navarra). Cells were cultured in RMPI 
1640 (Lonza) supplemented with 10% foetal bovine serum (FBS), 1% 
penicillin/streptomycin and L-Glutamine (all from Glibco®) and maintained in a 
humidified atmosphere of 5% CO2 at 37 ºC. For cytotoxicity studies cells were seeded 
(1000 cells/well in complete RPMI medium) in 96-well plates (100 µL/well) and allowed 
to adhere overnight. The samples to be tested were accordingly diluted in media and 
added directly to the cells (100 µL/well), in triplicate. After 72 h incubation at 37 ºC, 
cell viability was measured using MTT assay. Briefly, 100 µL/well of MTT reagent (0.25 
mg/mL in RPMI 1640) was added after the removal of the supernatants. Cells were 
incubated at 37 ºC for 1 h after which the medium was removed and the lysis solution 
added (DMSO, 200 µL/well). The absorbance was measured at 550 nm and the data 
represented as cell viability compared to the untreated control wells. 
Cell imaging. B16-F10-OVA cells were plated in an ibidi 15 well angiogenesis µ-Slide 
at a density of 4000 cells/well and allowed to adhere overnight in the presence of 
complete RPMI 1640 medium. Then, the medium was removed and fresh medium 
containing the rhodamine labelled Pt-loaded IONP micelles was added and incubated 
for 2 h. Nuclei were stained with Hoechst 33342 (5 µg/mL in RPMI medium) for 5 
minutes. After the nuclear staining the cells were washed twice with PBS (10 mM) and 
fresh medium was added prior to image acquisition. 
Cellular uptake by flow cytometry. B16-F10-OVA cells were plated in 96-well 
plates (105 cell/well) and allowed to adhere overnight in complete RMPI 1640 medium. 
Fluorescent formulations containing rhodamine labelled Pt-loaded IONP were diluted 
in medium accordingly and added to the cells at a final concentration of 1 mM Fe for 2 
h incubation at 37 ºC. The supernatant was removed and cells washed with PBS (10 
mM). The adherent cells were transferred to cytometer tubes and washed with PBS 
(10 mM). Cells were resuspended in a final volume of 200 µL of flow cytometry buffer 
(1% BSA, 0.1% sodium azide in PBS 10 mM) and analyzed by flow cytometry. 
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4.4.5 Labelling of the Pt-loaded IONP micelles with 67Ga 
67Ga was purchased as a citrate solution from Molypharma (Spain) (specific 
activity = 1.4 TBq/µmol), and converted to 67GaCl3 following a previously reported 
method. Briefly, the gallium citrate solution was passed through a light silica column 
cartridge (Sep-Pak, Waters) to selectively retain the radiometal. The cartridge was 
washed with ultrapure water (10 mL) and 67Ga was finally eluded with HCl 0.1 M. The 
eluate was collected in different 100µL fractions, and only those containing maximum 
activity concentration were used in subsequent labelling experiments. The eluded 
67GaCl3 solution (100 µL, c.a. 37 MBq) was then mixed with 50 µL of a Pt-loaded IONP 
micelle solution and diluted to a final volume of 350 µL in acetate buffer (pH = 3.8 ± 
0.1). After a 30 minute incubation at 70 ºC, the reaction crude was cooled down to 
room temperature and the labelled IONPs were separated via centrifugal filtration 
(6708 x g, 10 min) using AmiconUltracel 100k (MWCO 100 kDa) centrifugal devices 
(Merck) and washed twice with saline solution. The retentate was recovered from the 
filter by the addition of saline solution (100 µL). The total radioactivity in the filtrated 
and retentates was measured in a CRC-25R dose calibrator (Capintec, USA) in order to 
determine the incorporation efficiency.  
For stability studies, one batch of 67Ga-IONP-Pt micelles was fractions in different 
aliquots and incubated in the presence of the chelating agent DOTA (106 mol DOTA per 
NP mol) at 37 ºC. At different time points, the samples were filtered to separate the 
IONPs from the 67Ga complexed to DOTA and the radioactivity in the retentate and 
filtrate was measured in a 2470 WIZARD2 Automatic Gamma Counter (PerkinElmer). 
The dissociation of 67Ga from the radiolabelled micelles was calculated (expressed in 
percentage) at each time point as the ratio between the amount of radioactivity on the 
filter and the starting radioactivity. 
4.4.6 In vivo experiments 
Tumour inoculation. C57BL/6 mice (6-8 weeks old) were used for all in vivo 
experiments. B16-F10-OVA cells were used for the tumour inoculation and were 
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previously cultured similarly to what described for the in vitro experiments. Prior to 
injecting in vivo, cells were tested for mycoplasma using the commercially available 
MYCOALERT Mycoplasma Detection Kit (Lonza). For tumour inoculation 
30000cell/mouse were dissolved in Corning® Matrigel® Basement Membrane Matrix 
High Concentration diluted in PSB 10 mM (1:4 PBS:Matrigel®). All the material (tips, 
pipettes, syringes and storage vials) and the cell suspension in Matrigel® were kept in 
ice until use. The suspension was then loaded in a syringe and 100 µL/mouse injected 
using a 23 G needle. Animals were monitored for tumour growth using an electronic 
digital calliper 779A series (Starrett) until the tumour size was appropriate to start the 
therapy or SPECT/CT Imaging (~ 100 mm3, ~ 7 days from tumour inoculation). 
Biodistribution SPECT/CT studies. C57BL/6 mice (6-8 weeks old) were injected 
with 67Ga-IONP-Pt micelles in saline solution subcutaneously in the peritumoural 
region (110 µL, 15.69 MBq, 2.7 mg Fe/kg, 0.24 mg Pt/kg). With the mice under 
isofluorane anaesthesia (1.5-2% in oxygen), whole body SPECT/CT scans were acquired 
at 3 h, 24 h and 48 h post-injection. With the full ring detector, 360° data was acquired 
by rotating the collimator 45° (45 steps, 1°/step). Data was collected in an energy 
acquisition window from 125-150 keV to 84-102 keV and acquisition times from 60 min 
(80 s/step) to 45 min (60 s/step). During image acquisition, mice were kept 
normothermic using a heating blanket (Homeothermic Blanket Control Unit; Bruker 
BioSpin GmbH, Karlsruhe, Germany). After each SPECT scan, CT acquisitions were 
performed to provide anatomical information on each animal. The CT acquisition 
consisted of 220 views in 0.88° increments around the animal with 16 ms exposure per 
view. The X-ray tube settings were 70 kV and 32 mA. SPECT/CT images were acquired 
using the eXplore speCZT CT preclinical imaging system (GE Healthcare, USA).  
The system combines SPECT and CT on one gantry, allowing co-registration of the 
SPECT and CT data sets without additional post-processing. The SPECT scanner uses a 
stationary, full ring of CZT detectors and interchangeable rotating cylindrical 
collimators. An 8-slit collimator was used with a field of view of 32 and 78 mm in the 
transaxial and axial directions, respectively. The SPECT images were reconstructed 
using the OSEM iterative algorithm (5 and 15 subsets, 3 and 5 iterations) into 128 x 128 
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x 32 array with a voxel size of 0.4 x 0.4 x 2.46 mm, and were not corrected for scatter 
and attenuation. The CT images were reconstructed using a cone beam filtered back-
projection Feldkamp algorithm into 437 x 437 x 523 array with a voxel size of 0.2 x 0.2 
x 0.2 mm. At the end of the scanning procedure, the mice were culled by cervical 
dislocation and organs of interest removed for further ex vivo SPECT/CT imaging under 
the same conditions of the in vivo images. Analysis of the injected dose percentage per 
organ was performed by measuring their activity with a WIZARD22470 Automatic 
Gamma Counter (PerkinElmer). 
In vivo therapeutic efficacy. Therapy started roughly 1 week after the tumour 
inoculation (Day 0), when the tumour size reached ~ 100 mm3. The corresponding 
doses were injected on days 7, 10 and 13 in the subcutaneous peritumoural region (~ 
2 cm away from the tumour). In each case, 1 h prior to sample administration, TGF-β 
inhibitor LY364947 (1 mg/kg) was administered by intraperitoneal injection. The 
samples were prepared in saline solution (0.9% NaCl) with a fixed concentration of 
0.24 mg Pt/Kg for each dose and similar for all the groups (the injected iron 
concentration never exceeded 5 mg Fe/Kg). Similarly to the tumour inoculation step, 
animals were monitored for tumour growth using an electronic digital calliper 779A 
series (Starrett). Results of tumour volume, animal weight and survival rate are 
expressed as mean ± SEM (n = 5). 
4.4.7 Instrumentation 
HPLC-MS. Liquid chromatography was performed on an ACQUITY UPLC system 
(Waters, Milford, USA) with a conditioned autosampler at room temperature. The 
separation was carried out on an ACQUITY UPLC BEH C18 column (100 mm x 2.1 mm 
i.d., 1.7 µm). The column temperature was maintained at 40 ºC. The analysis was 
achieved using 100mM ammonium formate H2O/MeOH as the mobile phase with a 
flow rate of 0.3 mL/min. The injection volume was 5 µL. A Waters LCT-ToF premier 
Spectrometer (Waters, Milford, USA) was connected to the UPLC system via an 
electrospray ionization (ESI) interface. The ESI source was operated in W-optics 
positive ionization scan mode with the capillary voltage at 2.5 kV. The temperature 
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source and desolvation was set at 120 ºC. The cone and desolvation gas flows were 50 
L/h and 600 L/h, respectively. The instrument was calibrated over a 50-4000 m/z range 
before each measurement using a standard NaI solution (1 µM). All data collected in 
the centroid mode was processed using Masslynx software (Waters, Mildord, USA). 
NMR studies. 1H NMR spectra were recorded on a Bruker Avance 500 NMR 
spectrometer at 298 K. Data processing was carried out using Mnova software. 1H 
NMR spectra were recorded in D2O and the chemical shifts were expressed relative to 
the water peak at 4.8 ppm. 
XPS measurements. XPS experiments were performed in a SPECS Sage HR 100 
spectrometer with a non-monochromatic X-ray source (Magnesium K line of 1253.6 
eV energy and 250 W), placed perpendicular to the analyzer axis and calibrated using 
the 3d5/2 line of Ag with a full width at half maximum (FWHM) of 1.1 eV. The selected 
resolution for the spectra was 15 eV of Pass Energy and 0.15 eV/step for the detailed 
spectra of the Pt 4f peaks. The deconvolution of the Pt 4f peaks was carried out at 36 s 
of X-ray exposure. The deconvolution allowed to estimate the ratio of the Pt(II) and 
Pt(IV) states. All measurements were made in an ultra high vacuum (UHV) chamber at 
a pressure below 5·10-8 mbar. In the fittings Gaussian-Lorentzian functions were used, 
where the FWHM of all the peaks were constrained while the peak positions and areas 
were set free. 
TEM. TEM studies were conducted in a JEOL JEM-2011 electron microscope operating 
at 200 kV. The samples were prepared by depositing a drop of nanoparticle solution 
onto a copper specimen grid coated with a holey carbon film and allowing it to dry. For 
nanoparticle size determination a minimum of 300 particles were measured using the 
Image J software. 
ICP-MS. ICP-MS measurements were performed by the SGIker analytical facility of 
the University of the Basque Country (EHU/UPV, Leioa, Spain). ICP-AES measurements 
were carried out using a Perking Elmer optima 5300 DV (Perkin Elmer, Santa Clara, 
USA) employing an RF forward power of 1400 W, with argon gas flows of 15, 0.2 and 
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0.75 L/min for plasma, auxiliary and nebulizer flows respectively. Using a peristaltic 
pump sample solutions were taken up into a Gem Top Cross-Flow nebulizer and Scotts 
spray chamber at a rate of 1.5 mL/min. The instrument was operated in axial mode. To 
measure the iron content three wavelengths (238.024, 239.562, 259.939 nm) were 
selected and analyzed in a fully quant mode (three points per unit wavelength). A 
range of calibration standards were prepared using single element 1000 mg/L stock 
solutions (Fisher Scientific UK LDT) and Merk multi element standard (ICP Multi 
element standard solution VICertiPUR®) was used as a reference standard.  
ICP-MS studies were performed on an Agilent 7700x ICP-MS (Agilent Technologies, 
Palo Alto, USA) with a MicroMist micro-uptake glass concentric nebulizer (Glass 
Expansion, West Melbourne,  Victoria, Australia) and RF power of 1550 W with gas 
flows of 15 and 1.05 L/min for plasma an carrier respectively. To measure the platinum 
content three isotopic masses (m/z 194, 195 and 195) were selected and analyzed in 
spectrum mode (three points per unit point/mass and 200 ms integration time). In 
order to reduce MO+ formation in the plasma, the spray chamber was peltier cooled at 
2 ºC. A standard quartz torch with 2.5 mm internal diameter injector was used. Finally, 
standard nickel cones (sample and skimmer) were used. The optimization of the ICP-
MS conditions was achieved by adjusting the torch position sand tuning for reducing 
oxide and doubly charged ion formation with a standard tuning solution containing 1.0 
µg/L of 7Li, 24Mg, 59Co, 89Y, 140Ce and 205Tl in 1% HNO3. This equipment includes a 
collision cell (He gas, ORS3 system, Agilent Technologies) to discriminate spectral 
interferences with high performance.  
UV-Vis and Fluorescence spectroscopy. UV-vis measurements were performed 
in H2O using a Varian Cary 5000 spectrophotometer. Absorbance measurements on 
96-well plates were carried out on a TECAN Genios Pro 96/384 multifunction 
microplate reader. Fluorescence emission spectra were recorded with a Horiba Jovin 
Ibon Fluorolog fluorometer. 
DLS and ζ-potential. Particle size analysis was performed using a NanoSizer 
(Malvern Nano-ZS, UK) with 173° scattering angle at 25 ºC. Each sample was measured 
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at least in triplicate. Ζ-potential measurements were carried out with the same 
NanoSizer equipment at 25 ºC and a cell drive voltage of 20 V using a Smoluchowski 
model. 
Flow cytometry. All flow cytometry experiments were carried out in a FACS Canto II 
(BD Bioscience) system, which has an excitation source composed of three lasers: 
violet (405 nm), blue (488 nm) and red (633 nm). The laser excitation wavelength used 
for rhodamine B was 488 nm and the emission filter 585/42 nm. In all measurements 
cells were electronically gated based on forward and side scatter parameters and the 
not-singlet events leaved out based on forward area and height parameters. Each 
analysis represented the acquisition of 10000 cells per sample and data was analyzed 
with FlowJo LLC software. 
Fluorescence microscopy. Live cell fluorescence images were obtained using Zeiss 
Axio Observer wide field fluorescence microscope (Carl Zeiss, Germany). For Hoechst 
staining a colibri LED module was used for fluorescence excitation at 365 nm and   
Fluorescence emission was collected using a high-efficiency multi-band pass colibri 
filter set which included a 402-488 nm bandpass. A mercury short-arc HXP lamp was 
used for the excitation of rhodamine B and the fluorescent emission was collected 
using an emission filter with a 570-640 nm bandpass. Brightfield and fluorescence 
images were collected and processed using AxioVision software. 
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Conclusions 
■ During this thesis, two water soluble and biocompatible nanoparticle delivery 
systems based on iron oxide and gold nanoparticles have been synthesized and 
characterized.  
■ Following a prodrug approach, cisplatin and nedaplatin platinum (IV) prodrugs 
have been synthesized. 
■ The loading of both platinum based prodrugs and dsRNA into the different 
delivery platforms was achieved through the use of different strategies. The 
AuNP-PEI-Pt(IV) system has been based on outer-sphere interactions while the 
incorporation of poly(I:C) to the AuNP-PEI was achieved through electrostatic 
interactions. Finally, a covalent attachment strategy was selected in the case of 
IONP-Pt(IV) constructs. 
■ For all three systems, fluorescent labelling was incorporated and their 
intracellular uptake followed by live cell fluorescence microscopy and flow 
cytometry. 
■ In vitro cytotoxicity experiments were performed in different relevant cancer 
cell lines to assess the functionality of the systems. Overall, the use of PEI 
coated AuNPs resulted in an increased cytotoxic activity of both poly(I:C) and 
the platinum (IV) prodrug in human prostate cancer cells as well as breast and 
pancreatic cells in the case of the prodrug. The delivery of a Pt(IV) prodrug with 
IONP-filled micelles also increased the cytotoxic effect of the prodrug in an 
aggressive metastatic melanoma cell line. 
■ Notably, the use of AuNPs preferentially promoted the cytotoxic effect of 
poly(I:C) while its delivery with IONPs increased the immunostimulatory 
activity. 
Conclusions   
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■ For the IONP-Pt(IV) construct, a chelate free radiolabelling strategy allowed the 
incorporation of 67Ga radioisotopes and thus the visualization of the 
biodistribution in vivo in tumour bearing mice through SPECT/CT. The system 
successfully accumulated in the tumour area and also entered the lymphatic 
system reaching draining lymph nodes. 
■ Finally, the in vivo therapeutic efficacy was also studied for IONP-Pt(IV) and 
promising results were obtained. Initially, the co-injection of tumour cells with 
the appropriate samples lead to a therapeutic effect slightly better than 
cisplatin and a great improve in animal survival. A therapeutic treatment in 
tumour bearing mice led to the hypothesis that the system consists of both 
chemo and immunotherapeutic components with produce a combined effect 
that is notably enhanced in the presence of a TGF-β inhibitor. 
Overall this PhD thesis has not only been focused on the preparation of biocompatible 
nanoparticle based delivery vehicles for cancer therapy, but has also demonstrated the 
versatility of these systems to deliver different cytotoxic payloads.  In vitro studies 
carried out in relevant cancer cell lines prove the therapeutic potential of all constructs 
and although in vivo experiments were only carried out for one of the systems, very 
promising results were obtained. Beyond using the nanoparticles as delivery systems 
or imaging platforms, this work also highlights the possibility of using the nanoparticles 
as stealth immunotherapeutic agents to reach a combination therapy. 
Future work will involve more in depth in vitro and in vivo studies to investigate the 
role of the immune system in the therapeutic effect of the IONP-Pt(IV) construct as 
well as the development of the animal tumour model of prostate cancer (PC-3) to be 
able to explore the in vivo efficacy of PEI-AuNP based constructs. 
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